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Falls are a major cause of injury in older adults, leading to decreased quality of life and high 
economic cost. While the cause of falls is multi-dimensional, they have been linked to several 
characteristics seen in older adults. Specifically, this research focused on relating the use of 
medications and cerebrovascular changes with normal aging to changes in balance and gait, thus 
possibly increasing fall risk. The medications of interest were those with anticholinergic 
properties whose drug mechanism was to block the neurotransmitter acetylcholine. Medication 
use was measured using blood serum anticholinergic activity levels (SAA) of active receptor 
inhibitors. The cerebrovascular changes included those associated with white matter 
hyperintensities (WMH) in five regions of interest in the deep cerebral white matter detected by 
magnetic resonance imaging. The exact mechanism of action to negatively impact balance and 
gait is not well-known.   
Balance was assessed using measures of sway or center of pressure (COP) while gait was 
assessed using spatiotemporal variability parameters. Forty-eight participants, aged 65 to 80, 
were recruited. Balance and gait protocols were performed under single and dual-task digit recall 
conditions. Overall, performing tasks while standing or walking caused increased sway and 
temporal variability, respectively. When standing with eyes closed and not performing a task, 
participants’ sway increased with increasing WMH. However, no relationship was found with 
SAA. During gait, a positive relationship was found between WMH and cadence, stance time, 
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 v 
and step time variability, but only within two WMH regions. No relationships with SAA were 
identified. The lack of more correlations between the variables of interest could be attributed to 
the lack of variability in WMH and SAA along with the overall excellent health of the 
participants. These results indicate the potential for negative effects on balance and gait with 
healthy neural aging and anticholinergic drug use. Further investigations must be conducted to 
better understand the mechanism of action causing the negative impact on balance and gait. Once 
understood, better care can be taken to monitor medication use and provide therapeutic training 
to people at a higher risk for falls as related to medication burden and increased WMH with age.  
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 1 
1.0  INTRODUCTION 
With a steadily increasing population of older adults in the United States, falls in the elderly have 
become a well-known health problem. It has been estimated that one in three community-
dwelling adults over the age of 65 experiences a fall at least once a year (Hausdorff et al., 2001). 
This risk increases to one in two adults when looking at those over the age of 80 (Inouye et al., 
2009). Falls are associated with several adverse conditions and are often serious. In community-
dwelling fallers over the age of 65, decreased mobility and loss of independence are associated 
with approximately 20-30% of these falls (Sterling et al., 2001), leading to decreased quality of 
life. In 2007, falls were the leading cause of death from unintentional injuries in adults over the 
age of 65 (NCIPC, 2007). With such a high incidence of falls, the economic burden is also 
significant. In 2000, the direct medical cost estimate in the United States for all falls in those 
over 65 years was $19.2 billion (American Geriatrics Society, British Geriatrics Society, 
American Academy of Orthopaedic Surgeons Panel on Falls Prevention, 2001), and this estimate 
is expected to rise to $54.9 billion by 2020 (Englander et al., 1996). The United States Census 
Bureau has predicted that the population of people aged 65 and over will double by 2030 and 
those aged 80 and older will increase five times by 2050 (USCB, 2004). These statistics 
demonstrate that the issues associated with such a high fall incidence in this growing population 
will continue to be a major health, social, and economic problem in the United States without 
intervention or prevention.  
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The cause of falls in the aging population is multi-dimensional and can be attributed to 
many different factors. Factors shown to increase fall risk have been classified as intrinsic or 
extrinsic (Naqvi et al., 2009). Extrinsic factors are typically modifiable environmental factors 
such as poor lighting, lack of safety equipment, and loose carpeting. Intrinsic factors include but 
are not limited to age, muscle weakness, balance or gait deficiency, fear of falling, cognitive 
impairment and brain dysfunction, and the use of high-risk medications (Clyburn and 
Heydemann, 2011). Older adults will typically experience one or more of these risk factors, and 
previous work has demonstrated a cumulative effect when the number of risk factors increases. 
Community-dwelling adults over the age of 65 increase their fall risk from 27% to 78% when the 
number of applicable risk factors increases to four or more (Tinetti et al., 1988). While some 
intrinsic factors such as age or gender cannot be modified, interventions specific to other 
intrinsic factors, such as modifying medication use and strength training may be of importance 
for minimizing fall risk in the aging population. By understanding the mechanisms and 
consequences of factors such as medication burden, muscle weakness, and cognitive decline on 
performance and fall risk, training programs and more effective patient management may be 
developed to help minimize and prevent falls in older adults. 
1.1 BALANCE, GAIT AND THEIR RELATIONSHIP TO FALLS  
Risk factors for falls in older adults investigated in the present work include those related to 
postural stability during standing balance and gait characteristics during over ground walking.  
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1.1.1 Postural Control and Balance 
Maintaining balance requires integration by the central nervous system (CNS) of three different 
systems: visual, proprioceptive, and vestibular. It has been shown that together, these systems 
work in a feedback loop to maintain balance and produce counteractive motions to the constant 
displacement of gravity acting on a person during upright stance (Johannson, 1991; Horak & 
Macpherson, 1996; Peterka, 2002). Vision detects head orientation with respect to the 
surrounding environment, proprioception detects lower limb orientation with respect to the 
ground or support surface, and the vestibular system detects orientation changes of the head due 
to the force of gravity (Peterka, 2002). While there is a certain level of redundancy across the 
systems, perturbing one or two of the systems requires combined efforts and adaptation of the 
remaining systems so that a person will remain upright. This method, better known as sensory re-
weighting, allows the body to dynamically react to the ever-changing demands of the 
environment (Peterka, 2002; Mahboobin et al., 2005; Maurer et al., 2006). An example of the 
loss of one system would be asking someone to stand with his or her eyes closed. By removing 
the visual input to the CNS, the vestibular system and proprioception must re-weight their 
responsibilities and take over the loss of visual input while still keeping the body upright 
(Peterka, 2002). The interactions of these three systems then, are ultimately determined by their 
health and integration, the information available to them, and the environmental cues from the 
surroundings (Redfern et al., 2001).       
Decrements in balance in older adults have been classified as an intrinsic risk for falls. 
Previous research has demonstrated a significant difference between older adults classified as 
fallers and non-fallers in clinical assessments such as an increased score on the Timed Up and 
Go Test (Podsiadlo et al., 1991; Gunter et al., 2000) and a decreased score on the Berg Balance 
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Scale (Berg et al., 1992; Shumway-Cook, 1997) in fallers compared to non-fallers. These clinical 
assessments are widely utilized, easily administered, and often used as a guideline for 
intervention and assessing intervention effectiveness. While it is beneficial to understand the 
differences between these groups and identify those at a higher risk for a first or recurrent fall, 
these assessments are subjective, self-paced and controlled in a predictable environment (Desai 
et al., 2010). Quantitative analyses of postural control using validated laboratory protocols such 
as dynamic posturography have also shown a decline in balance performance with age (Peterka 
& Black, 1990; Ledin et al., 1990; Wolfson et al., 1992). The increased instability in older adults 
with the changes observed in these analyses can be linked back to an increased fall risk in this 
population.  
As mentioned previously, the three systems must be working properly to maintain an 
upright posture and avoid losing balance. It is the malfunction of one of these systems that would 
lead to the decline in performance during a balance task (Speers et al., 2002). While the exact 
mechanism of decline is not particularly known, each system can be analyzed independently for 
change. Changes with age to the vestibular system can include a decrease in the number of hair 
cells in the individual organs within the system or a decrease in conducting fibers located in the 
vestibular nerve (Rosenhall, 1973; Bergstrom, 1973). With regards to vision, it has been shown 
that older adults experience a decrease in visual acuity and sensitivity during low frequency 
motion (Sekuler & Hutman, 1980). Studies have even shown that older adults rely more on 
visual information to maintain balance during quiet stance (Sheldon, 1963; Alexander, 1994). 
Finally, peripheral neuropathy, leading to decreased proprioception, is also common in older 
adults. One in five older adults suffers from peripheral neuropathy, thus decreasing the sensory 
feedback from proprioception, increasing the risk of poor balance performance and increasing 
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the risk of falls (Richardson, 1996). Degradation in one or more of these systems in addition to 
decreased neural processing and increased muscle weakness with age will all have a negative 
impact on postural control and standing balance in older adults, increasing the likelihood of falls. 
1.1.2 Spatiotemporal Gait Characteristics during Normal Walking 
In addition to postural control during stance, spatiotemporal gait characteristics are also 
important in understanding fall risk in older adults. Previous research has shown several links 
between falls and these variables of interest (Beauchet et al., 2005; Dubost, et al. 2006). Gait 
speed has been shown to contribute to falls in older adults when decreased during normal 
walking (Luukinen et al., 1995; Cesari et al., 2005; Montero-Odasso et al., 2005). This decrease 
in speed, however, may actually be an indicator for other functionally limiting co-morbidities 
(Studenski, 2009). Gait variability has also been shown to predict falls and decreased physical 
function in older adults (Hausdorff, 2007; Brach et al., 2008). Gait variability is a measure of 
intra-individual fluctuation in a particular variable of gait from one step to the next. It is said to 
represent alterations to the intrinsic control mechanisms of gait from a decline in several factors 
including changes in the CNS (Maki, 1997; Brach et al., 2005). Gait variability has been shown 
to increase with age. Increased variability, such as in double support or stance time, has been 
directly associated with mobility disability and fall risk in older adults (Hausdorff et al., 1997; 
Maki, 1997; Hausdorff et al., 2001; Brach et al., 2007). Increased gait variability is a direct 
reflection of an inconsistent pattern of walking due to a reduction in postural control (Hollman et 
al., 2007). 
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1.2 RELATIONSHIP BETWEEN ANTICHOLINERGIC BURDEN AND FALL RISK  
One intrinsic factors shown to impact the risk of falls in adults over the age of 65 is medication 
use (Naqvi et al., 2009). Specific classes of medications commonly prescribed to the aging 
population have been previously demonstrated as an increased risk for falls including 
psychotropics such as benzodiazepines and antidepressants (Monane & Avorn, 1996; Cumming, 
1998; Landi et al., 2005; Howland, 2009), cardiovascular drugs such as nitrates (Cumming, 
1998), and non-steroidal anti-inflammatory drugs (Cumming, 1998). Another key drug group 
that is commonly prescribed to older adults and available over-the-counter is a class of drugs 
known as anticholinergics or antimuscarinics. Drugs exhibiting anticholinergic properties act by 
inhibiting the neurotransmitter acetylcholine from binding to the muscarinic receptors in the 
brain. The target receptors are primarily located on motor end plates of skeletal muscle and 
autonomic effector cells innervated by the parasympathetic nerves. The targets’ cell bodies are at 
their highest densities within the CNS, hippocampus, cortex, and thalamus (Brunton et al., 2011). 
Research has shown that there are more than 600 anticholinergic drugs available (Tune, 2001) 
with 11% of these drugs commonly prescribed to the older adult population (Tollefson et al., 
1991). Examples of these commonly prescribed drugs include diphenhydramine, codeine, 
diazepam, prednisolone, and clindamycin (Tune et al., 1992). 
Anticholinergics target several different organ systems including the CNS, eyes, 
cardiovascular and respiratory systems, and gastrointestinal and genitourinary tracts. There are 
many beneficial clinical applications of these drugs including motion sickness control, tremor 
reduction in Parkinson’s patients, bronchodilation during allergic reaction and asthma attacks, 
cardiac rhythm regulation, and treatment of urinary incontinence. However, successful treatment 
of these systems is typically accompanied by adverse drug reactions (ADRs) including lethargy, 
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hallucinations, amnesia, dry eyes, fibrillation, and significant urine retention (Katzung et al., 
2009). In addition to the ADRs mentioned, research has also demonstrated that the use of 
muscarinic blocking drugs has been associated with a decline in cognitive function including 
working memory, episodic memory, attention, and processing speed (Sunderland et al., 1988; 
Flicker et al., 1992; Molchan et al., 1992; Mulsant et al., 2003; Landi, 2007). ADRs related to 
anticholinergic drug use are often enhanced in older adults as they are typically taking multiple 
medications at once. In a study on nursing home patients, 21-32% of residents were taking two 
or more drugs with anticholinergic properties (Blazer et al., 1983), putting them at an increased 
risk for multiple ADRs and decreased quality of life.  
With an increase in the number of medications taken by older adults and the high number 
of drugs exhibiting anticholinergic properties available by prescription and over-the-counter, it 
should be of concern that community-dwelling older adults are exposed to anticholinergic ADRs 
that may impact daily living and potentially place them in a life-threatening situation. In fact, 
anticholinergic medications have been linked to falls in older adults (Landi et al., 2005; 
Aizenberg et al., 2002; Wilson, 2011). However, these studies were derived from hospital or 
residential care facility inpatient fall histories, not from community-dwelling older adults whose 
medication burden may be just as significant if not worse because of access to medications. With 
regard to the population of interest, motor impairments while taking anticholinergics have been 
reported. Cao and colleagues (2008) found that in older women, anticholinergic burden was 
associated with decreased gait speed and decline in ability to balance in side-by-side, semi-
tandem, and tandem stance for 10 seconds. Nebes and colleagues (2007) also found decreased 
gait speed with increased anticholinergic medication levels. Landi and others (2007) showed a 
significant decrease in average score on the Short Physical Performance Battery (SPPB) in 
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anticholinergic drug users over the age of 80. Finally, Hilmer (2007) demonstrated that increased 
anticholinergic drug burden in community-dwelling adults aged 70 to 79 is associated with 
decreased physical function as measured by the Health ABC performance score. 
While insight into the relationship between anticholinergic medications and fall risk is 
important, previous research demonstrating this relationship is limited to qualitative and 
subjective measures of balance and gait. Additionally, the mechanism of action of 
anticholinergic medications to inflict decline in both balance and gait is unknown. To better 
understand the mechanism of action, more quantitative measures of balance and gait, outside of 
simple gait speed, are needed to identify the potential impact of anticholinergic medications on 
balance and gait. Dr. Robert Nebes, the primary investigator of this research project, has shown 
in completed pilot work that increased levels of anticholinergic medications were significantly 
associated with increased sway in the medial-lateral direction without a concurrent task and 
increased stride time variability in the presence of a concurrent task. This pilot work was 
completed with the use of only eight participants. The significance of these results in such a 
small sample size is direct motivation to pursue this research on a larger sample of participants to 
better understand the impact of anticholinergic medications on balance and gait.  
1.3 RELATIONSHIP BETWEEN WHITE MATTER HYPERINTENSITIES AND 
FALL RISK 
Other points of interest in the aging population and fall risk are age-related changes in the brain. 
Just as anticholinergic drugs act on the brain to produce decrements in motor control and 
physical performance, changes within the brain have also been linked to decreased motor 
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function in older adults. One group of changes that have been identified as markers of 
cerebrovascular disease are better known as white matter hyperintensities (WMH) which are 
found in the deep cerebral white matter. These areas are represented as high signal intensities on 
magnetic resonance imaging (MRI) and are common in both normal and cognitively impaired 
older adults (Appel et al., 2009; Ota et al., 2010). The deep vessels located in the white matter 
experience hyperprofusion and disruption of the blood-brain barrier, leading to chronic plasma 
leakage and lesion formation within these areas (Pantoni & Garcia, 1997; O’Sullivan, 2002; 
Topakian, 2010). The physiological consequences of developing WMH have been associated 
with demyelination, loss of axons, gliosis, and dilation of the periventricular space (Ota et al., 
2010). Interestingly, 11-21% of healthy adults aged 64 have visible WMH on MRI, and 94% of 
healthy adults show similar results by the age of 82 (Debette & Marcus, 2010). In addition to 
age, several health conditions serve as risk factors for developing WMH including prior 
myocardial infarction or stroke, hypertension, elevated cholesterol, and heart disease (Bretler, 
1994).   
Since WMH are associated with neural changes in both healthy older adults and those 
with co-morbidities, it is of interest to understand how these changes may affect cognitive and 
physical function. As with anticholinergic drugs, WMH have been associated with declines in 
cognitive function (Bretler, 1994; Debette & Marcus, 2010). Of greater interest is their impact on 
balance and gait. Several studies have been conducted into understanding the changes in physical 
function in older adults with WMH, correlating this to fall risk. As with increased anticholinergic 
drug use, decreases in performance during the SPPB have been shown with increased WMH 
levels (Benson et al. 2002; Wolfson et al. 2005).  Murray and colleagues (2010) found a decrease 
in visual gait performance and gait speed with an increased level of WMH, suggesting that 
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WMH result in overall motor slowing. Another study looking at auditory cued step-initiation and 
WMH found greater processing time to initiate a response with higher levels of WMH, 
indicating a risk for decreased mobility and increased fall potential (Sparto et al., 2008). Finally, 
Rosano and others (2006) showed decreased gait speed and increased stride and double support 
time to be associated with increased WMH, indicating deteriorations in gait with the presence of 
cerebrovascular changes and aging. Other than speculation as in with anticholinergic 
medications, the exact mechanism of WMH for eliciting an impact on balance and gait remains 
unknown. Additionally, other than the work of Sparto and colleagues (2008), and Novak and 
colleagues (2009), current research has looked only into overall brain WMH. It is of interest to 
identify if specific regions of the brain associated with motor, executive, and cognitive function 
are more related to decrements in balance and gait than overall WMH.  
1.4 INTERACTION EFFECTS OF ANTICHOLINERGIC DRUGS AND WHITE 
MATTER HYPERINTENSITIES 
With evidence pointing to several detrimental effects when taking anticholinergic drugs or in the 
presence of WMH with age, it should also be of interest to investigate any potential relationship 
between the combination of these independent factors. Previous research has demonstrated a link 
between individuals taking anticholinergic drugs and the presence of WMH with a decline in 
cognition (Nebes et al., 2005). According to Bocti and colleagues (2005), one possible 
mechanism of cognitive decline is the interference of WMH with cholinergic pathways located 
in the white matter. The location of these pathways leaves them susceptible to vascular lesions 
associated with WMH (Seldon, 1998). Both animal and human models have shown an increased 
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sensitivity to anticholinergic drugs such as scopolamine when accompanied by the interference 
of cholinergic pathways in the aging brain (Flicker et al., 1992; Ray et al., 1992). Another 
mechanism of action when combining the effects of WMH with anticholinergic drugs could be 
the increased permeability of the blood-brain barrier. Starr and colleagues (2003) showed a 
positive relationship between permeability and WMH. An increase in WMH in healthy adults 
resulted in an increased permeability. As a result, anticholinergic medications may be able to 
better penetrate the neural tissue and cause greater effects when taken by older adults with high 
levels of WMH. With evidence in cognitive decline from combined effects, it may be suggested 
that the increased fall risk associated with WMH or anticholinergic drugs alone may actually be 
amplified when occurring simultaneously in otherwise healthy older adults.   
1.5 DUAL-TASK EFFECTS ON BALANCE AND GAIT 
Of added interest in the participant population recruited for this proposed work is the impact of 
altered attention on balance and gait. As stated previously, both anticholinergic drugs and WMH 
have been associated with cognitive decline including slowing of processing and changes in 
attention (Sunderland et al., 1988; Flicker et al., 1992; Molchan et al., 1992; Mulsant et al., 2003; 
Landi, 2007; Appel et al., 2009; Ota et al., 2010). While this may also be attributed to healthy 
aging where it is common to see a decrease in executive function (Herman et al., 2010), it is of 
interest to see if there is a correlation between high levels of anticholinergic drugs and WMH 
with attention and performance during a dual-task paradigm. A dual-task paradigm is used to 
investigate the cognitive demands of postural control while performing a separate nonpostural 
task such as repeating numbers or reading. The thought is that the control of posture and 
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maintaining upright stance must compete with the secondary exercise for the available central 
resources (Prado et al., 2007). Previous research has shown that with age, control of balance and 
gait becomes difficult as there is a decline in the sensorimotor information available. This then 
requires more attention to safely maintain an upright posture (Li et al., 2001; Bloem et al., 2003). 
Falls in older adults have been associated with activities requiring divided attention between two 
tasks such as walking while talking (The Prevention of Falls in Later Life, 1987; Bergland et al., 
1998).  
Several studies have revealed an increase in postural sway while performing a cognitive 
challenge task under quiet stance (Maylor & Wing, 1996; Shumway-Cook & Woollacott, 2000; 
Teasdale & Simoneau, 2001). Others have identified decreased gait speed and increased gait 
variability when walking while performing a cognitive task (Hausdorff et al., 2003; Sheridan et 
al., 2003; Beauchet et al., 2005). Interestingly, Bloem and colleagues (2001) found that older 
adults experiencing a cognitive task while asked to maintain balance use what they have called a 
‘posture first’ strategy. With this, older adults prioritize maintaining balance over successful 
completion of the secondary task, potentially trying to avoid falling. With these results, it can be 
concluded that there must be some aspect of attention and cognition responsible for execution of 
both balance and gait.  
1.6 SUMMARY 
With previous work documenting declines in motor performance, physical function and 
increased fall risk with anticholinergic drug use and WMH, a thorough analysis must be 
conducted to better understand the impact of these drugs and neural changes on balance and gait 
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in community-dwelling older adults. Specifically, looking at postural sway and temporal gait 
characteristics, the effects of these intrinsic factors on balance and gait can be quantitatively 
obtained, revealing potential underlying mechanisms of how anticholinergic medications and 
WMH are related to fall risk in older adults. These assessments will be conducted under both 
control and cognitive tasks. By understanding the characteristics of each participant’s balance 
and gait prior to and during a cognitive task, there may be a better understanding of functional 
performance under cognitive loads but also the correlation of this performance to anticholinergic 
drugs and WMH. Finally, since WMH have been shown with normal aging, it is also of interest 
to understand the relationship between older adults currently taking anticholinergic drugs and 
their levels of WMH as detected by MRI. Understanding these two risk factors for falls in the 
older population may allow clinicians to better medicate, educate, and intervene with their 
patient populations to reduce the risk and number of falls. 
1.7 SPECIFIC AIMS 
The long term goal of this project is to better understand the possible mechanisms by which 
decrements in balance and gait are associated with anticholinergic medications, white matter 
hyperintensities, and their combined effects. With knowledge of how change is inflicted, specific 
training protocols and medication monitoring can be better conducted to improve physical 
function and minimize the potential risk for falls in older adults. Understanding these factors and 
their relationships to balance and gait may provide additional insight into the mechanisms of 
action. Previous work is limited to qualitative analyses, simple measures, and the lack of 
combining these factors of interest. With this, the overall purpose of this research study was to 
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understand the relationships between anticholinergic burden, WMH, and their combined effects 
on balance outcome measures, gait speed, and temporal gait variability.   
The first focus of this research project is to understand the impact of anticholinergic 
medications on balance and gait. Specifically, anticholinergic medications have been shown to 
impact cognitive function. Thus, it is likely that anticholinergic medications will have a larger 
impact on balance and gait when performed during a cognitive challenge task. This relationship 
will be investigated using serum anticholinergic activity (SAA) of blood to quantify medication 
burden.  
 
Specific Aim 1: To determine whether the level of exposure to anticholinergic 
medications as measured by SAA affects standing balance and gait, thus increasing fall risk.  
Hypothesis 1: Individuals with higher levels of SAA will experience impaired balance 
(increased sway and sway velocity) and gait (decreased gait speed and increased temporal 
variability) compared to individuals with lower levels of SAA. 
Hypothesis 2: The impaired relationship of SAA level to balance and gait will be 
amplified when the balance and gait tasks are performed during a cognitive challenge task.   
 
The second focus of this research project is to understand the impact of cerebrovascular 
disease on balance and gait. Specifically, cerebrovascular disease has been shown to affect 
processing speed and attention in older adults. This relationship will be investigated using 
quantified levels of cerebrovascular disease as defined by WMH on MRI. 
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Specific Aim 2: To determine whether the level of cerebrovascular disease (WMH) 
affects standing balance and gait, thus increasing fall risk. 
Hypothesis 1: A decline in balance (increased sway and sway velocity) and gait 
(decreased gait speed and increased spatial variability) will be seen in individuals with higher 
levels of WMH. 
Hypothesis 2: The relationship of WMH to negative effects on balance and gait will be 
enlarged when the balance and gait tasks are performed during a cognitive challenge task.   
 
Finally, the third focus of this research project is to understand if the combination of 
anticholinergic burden and cerebrovascular disease in older adults will have an even greater 
impact on balance and gait. If SAA was linked to decrements in cognition and WMH has been 
linked to slower processing speed and decreased attention, it should be consistent that combining 
both detrimental variables should result in even more detrimental effects on balance and gait. 
This relationship will be assessed using WMH levels located in the neural tracts containing 
cholinergic fibers.  
 
Specific Aim 3: To determine whether the level of combined effects of anticholinergic 
medications and WMH affect standing balance and gait, thus increasing fall risk. 
Hypothesis 1: Individuals with higher levels of WMH in the cholinergic tracts will 
experience impaired balance (increased sway and sway velocity) and gait (decreased gait speed 
and increased temporal variability) compared to individuals with lower levels. The level of 
impairment will be greater than that seen in individuals with decrements only due to WMH or 
only due to SAA.  
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Hypothesis 2: The impaired relationship of WMH in the cholinergic tracts to balance and 
gait will be amplified when the balance and gait tasks are performed during a cognitive challenge 
task. 
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2.0  RESEARCH METHODS 
2.1 ASSESSMENT OF SERUM ANTICHOLINERGIC ACTIVITY 
To quantify the anticholinergic burden in the participants recruited for this study, 10 cc of blood 
from each participant were collected by a clinical phlebotomist at the Western Psychiatric 
Institute and Clinic, Pittsburgh, Pennsylvania and analyzed to determine the individual serum 
anticholinergic activity (SAA). Quantification of SAA was done using a radioreceptor assay 
developed by Tune and Coyle (1981). Quinuclidinyl benzilate (3H-QNB) binds specifically and 
with a high affinity to muscarinic cholinergic receptors. Anticholinergic drugs compete with 3H-
QNB at the receptor site as they are muscarinic inhibitors. With this, the ability of 3H-QNB to 
bind to muscarinic receptors is reduced in proportion to the concentration of anticholinergic 
drugs in the blood serum collected. Using homogenized rat forebrain bound with 3H-QNB, a 200 
µL control serum without anticholinergic properties and added atropine was assayed to 
determine a standard curve for the amount of 3H-QNB displaced for the specific neural tissue 
sample and amount of atropine used. Participant’s SAA was expressed as the amount of atropine 
in a 1 mL sample of serum without anticholinergic properties that would be needed to inhibit the 
same amount of 3H-QNB from binding to the muscarinic receptors of the rat forebrain as the 
participant’s sample. The SAA level was expressed as pmole mL-1 of atropine equivalent serum. 
Using this method of reporting SAA, the serum levels of all anticholinergic drugs taken by 
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participants and unbound to proteins, including drug compounds, supplements, and their 
metabolites, could be quantified (Mulsant et al., 2003). 
2.2 ASSESSMENT OF WHITE MATTER HYPERINTENSITIES 
2.2.1 Magnetic Resonance Imaging 
Each participant underwent magnetic resonance imaging (MRI) at the UPMC MR Research 
Center to quantify WMH. The scan was acquired using a Siemens 3 Tesla TIM TRIO scanner 
with eight channel coil (Siemens Medical Solutions USA, Inc., Malvern, PA). Axial series 
images along the transverse plane were acquired for each participant and included T1-weighted, 
fast spin-echo T2-weighted, fast fluid-attenuated inversion recovery (FLAIR), diffusion-tensor 
imaging, and magnetization-prepared rapid acquisition gradient-echo (MPRAGE).     
2.2.2 Processing Magnetic Resonance Imaging Data 
Analysis of all imaging data was conducted at the Geriatric Psychiatry Neuroimaging Lab under 
the supervision of Dr. Howard Aizenstein, M.D., Ph.D. Processing was performed using an 
automated method for segmenting and localizing WMH developed by Wu and colleagues 
(2006b). First, an intensity histogram of the FLAIR image was created to determine white 
matter, grey matter and cerebrospinal fluid. From this, WMH seeds were automatically 
generated. Using a fuzzy connected algorithm and individual parameters for each seed, WMH 
clusters containing the individual seeds were generated based on the fuzzy-connectedness or 
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affinity between voxels within the fuzzy object for the particular seed of interest. Upon 
generation of the individual WMH clusters from the identified seeds, the scattered WMH clusters 
were combined into final WMH segmentation volumes. Next, to localize the previously 
segmented WMH into regions of interest, an Automated Labeling Pathway (ALP) was 
employed. ALP was previously developed and has been used to automatically label specific 
anatomic regions of interest on structural MRI (Wu et al., 2006a). A high resolution reference 
image, the MNI colin27 image (MNI colin27), was registered to each participant’s T1-weighted 
images using ALP. The T1-weighted images were preprocessed in order to match both the 
orientation and composition of the reference image. The Johns Hopkins University White Matter 
Atlas, which had been defined on the reference image, was then warped into each participant’s 
registered image, creating anatomical definitions of individual regions within the brain image 
(Wakana et al., 2004). The T-1 image with landmarks was then masked onto the segmented 
FLAIR image so that areas defined as WMH were also given an anatomical point of reference.  
2.2.3 Regions of Interest 
A total of 20 individual tracts, as localized using the Johns Hopkins University White Matter 
Atlas, were defined for each image along with the sum of these tracts (WMH ALL) and total 
white matter volume. The total white matter volume was significantly correlated with WMH 
ALL with a Pearson correlation coefficient of 0.93 and p-value <0.0001. With such a high 
correlation, only WMH ALL was selected for the analysis. Individual tracts were also identified 
as either containing (CHOL) or not containing cholinergic fibers (NON-CHOL). Since 
anticholinergic burden and its interaction with WMH in the participants of this work are of 
importance, these measures may allow quantification of this interaction. In addition to overall 
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WMH and cholinergic tracts, the analysis also utilized eight of the specific tracts, combined into 
three variables of interest. The sum of the left and right anterior thalamic radiation and the left 
and right corticospinal tract was defined as AACC. The left and right superior longitudinal 
fasciculus were summed and defined as SS. The frontal and occipital regions of the corpus 
callosum were also summed and defined as CC. The tracts the their combinations selected for 
analysis were based on previous research linking the importance of the tract to either or a 
combination of motor function, cognition and processing, and executive function (Sheline et al., 
2008; Sparto et al., 2008; Duering et al., 2011). Quantification of WMH was done using a 
normalized voxel count in which the number of voxels containing WMH in the region of interest 
was divided by the total brain volume, yielding a percentage of total brain volume. 
2.3 COGNITIVE TASK 
2.3.1 Determining Cognitive Task Difficulty 
Half of all balance and gait trials were conducted under a cognitive dual-task condition. The 
chosen task, digit recall, was challenging, adjustable to individual cognitive capacity, and 
provided by an auditory stimulus. This task has been previously used in older adults and was 
shown to make a major demand on participants’ working memory (Nebes et al., 2001).  Each 
participant was first assessed at the Western Psychiatric Institute and Clinic, Pittsburgh, 
Pennsylvania by one of the study’s co-investigators to determine participant-specific digit spans. 
Starting with two digits, a list of numbers was presented at a rate of one digit per second, and the 
participant was asked to recall them in the reverse order. For example, if the participant was 
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given 1, 4, they would repeat back “4, 1”. The participant received two lists of numbers of the 
same length. The number of digits was increased by one if the participant could correctly repeat 
one of the two lists in the previous series. This was continued until the participant could not 
correctly repeat back either of the lists within a series or the participant was successful with a 
string of eight digits. The participant’s digit span for the testing duration was set at the longest 
number of digits that could be correctly recalled for at least one of the two lists given. This span 
was between two and eight digits. 
2.3.2 Cognitive Challenge Task during Data Collection 
During both standing balance and gait trials, participants experienced one of three cognitive 
conditions. The first, no task (NT), was a control task in which participants did not receive an 
auditory stimulus. The second, forward (F), was a cognitive challenge task in which participants 
were asked to repeat the list of words presented to them in the same order in which they were 
received. For example, if the participant was given 1,5,7,8 followed by the word repeat, the 
participant would respond “1,5,7,8”. The third task, backwards (B), was a cognitive challenge 
task in which participants were asked to repeat the list of words presented to them in the opposite 
order in which they were received. For example, if the participant was given 2,5,6,9 followed by 
the word backward, the participant would respond “9,6,5,2”. The number of digits presented to 
each participant was based on the previous screening as described above and remained constant 
for all trials. Using Logitech ClearChat PC Wireless headphones (A-00007, Logitech, Fremont, 
CA), the auditory stimulus was provided into the headset and participant responses were 
recorded using the attached microphone. All balance and gait trials were conducted in groups of 
three. With this, the order of cognitive conditions remained constant for each participant. The 
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first trial of each group was always NT. The second and third were randomized such that it was 
either F then B or B then F. The order of the second and third trials remained consistent for the 
entire testing session. 
2.3.3 Cognitive Task Performance Scoring 
Performance on the cognitive task was scored at the conclusion of the balance and gait 
assessments at the Western Psychiatric Institute and Clinic. Scoring was based on a system 
allowing partial credit for correctly recalling certain portions of the list. Digits recalled were 
counted as correct if: the first or last digit of a string was correctly recalled, any correct digits 
adjacent to a correctly recalled first or last digit was recalled, and any correct sequence of three 
or more digits anywhere in the response was recalled (Drachman & Zaks, 1967). For example, if 
the list given was 1,2,3,5,7,9 and the participant was to repeat it backwards, the participant 
would receive a score of six out of six for this list if 9,7,5,3,2,1 was repeated. If 9,7,3,5,2,1 was 
repeated, the participant would receive a point for the 9, 7, 2 and 1, giving a score of four out of 
six. Finally, if 9,8,7,5,3,1 or 9,7,7,5,3,1 was repeated, the participant would receive a score of 
three out of six. For each scenario, the 9, 7, 5, 3 and 1 are correct. The group of 7 5 3 forms a 
correct sequence of three digits. However rather than scoring four out of six, one point is 
deducted from each score because an intrusion, or a digit that is not part of the series, is inserted 
into the first scenario, and a number is repeated in the second scenario. The number of correct 
digits is averaged over the number of digits presented in 60 seconds. This number is then divided 
by the participant’s specific digit span and documented as a percent correct for that task. For 
example, a participant averaged 3.2 digits correct over 60 seconds with a digit span of 5. For that 
trial, the participant’s cognitive task accuracy would be 64%. The accuracy score was then 
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normalized to a seated accuracy score by subtracting the accuracy of performance during the 
specific trial of interest from the accuracy of a seated baseline trial conducted prior to testing. 
2.4 EQUIPMENT 
2.4.1 Testing Area 
All data to perform the postural and gait analyses were collected in the Human Movement and 
Balance Laboratory located at the University of Pittsburgh, Pittsburgh, Pennsylvania (Figure 1). 
The laboratory was equipped with two embedded Bertec force plates (4060A, Bertec, Inc., 
Columbus, OH) and a Vicon 612 motion capture system. Eight IR M2-cameras (Vicon, 
Centennial, CO) captured motion data at 120 Hz while analog signals from the forceplates were 
recorded at 240 Hz from a 12-bit National Instruments A/D converter.   
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Figure 1: Schematic depicting laboratory layout. Eight Vicon motion capture cameras 
shown around room with embedded forceplates indicated by rectangles labeled P1 and P2. 
 
2.4.2 Motion Capture Set-up 
Using the Vicon 612 motion capture system and Vicon Workstation, three dimensional 
trajectories were collected and reconstructed for all standing balance and gait trials. For standing 
trials, participants were instrumented with a custom marker set including 14 reflective markers. 
During gait trials, an additional 12 reflective markers were added to the feet, generating 26 
trajectories (Figure 2 and Figure 3). All segments were considered rigid bodies for analysis 
purposes.  
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Figure 2: Motion capture marker placement on the anterior (left) and posterior (right) 
pelvis and upper body. The sternum marker, used for gait speed, is indicated by the red circle. 
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Figure 3: Anterior (left), lateral (middle), and medial (right) views of motion capture 
marker placement on polyvinyl soled shoes for testing. A total of nine markers were used on 
each foot including one on the lateral malleolus (not shown). 
 
2.4.3 Footswitches 
Participants’ shoes were instrumented with custom on-off membrane footswitches for all gait 
trials. These switches were used to temporally identify heel contact and toe off events during 
gait. On the sole of the shoe, the toe switch was placed on the anteriomedial edge, and the heel 
switch was placed on the posteriolateral edge (Figure 4). Switches were rated for five ounce 
activation. Analog voltages were collected and digitized using a BluSentry Bluetooth Adapter 
(RN-800S-CB, Roving Networks, Los Gatos, CA) mounted in an electronics enclosure worn on 
the waistband. The digitized signals were then transmitted wirelessly to a paired Bluetooth 
receiver (TBW 104UB Version 2.1R, TRENDNET, Torrance, CA) at 120 Hz.   
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Figure 4: Polyvinyl soled shoe instrumented with two simple on-off membrane switches 
for temporal heel contact and toe off events. 
2.5 PARTICIPANTS 
A total of 48 older adults (27 females, 21 males) were recruited to participate in this study (Table 
1). Written informed consent was obtained prior to participation and approved by the University 
of Pittsburgh Institutional Review Board. Participants were screened for neurological, visual, 
orthopedic, cardiovascular, medication use, and any other physical abnormalities that would 
prevent them from standing with their feet together or affect their balance or gait. All participants 
were asked to wear comfortable clothing with a shirt that could be tucked in. Additionally, 
participants were outfitted with the same polyvinyl, flat soled shoe to maintain consistency in 
equipment used to obtain footswitch data.  
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Table 1: All participant characteristics including mean, (SD), [range] 
 
Age [years] Height [m] Weight [kg] 
75.6 
(4.05) 
[70.3-83.5] 
1.68 
(0.09) 
[1.52-1.87] 
75.9 
(14.7) 
[47.4-119.6] 
2.6 STANDING BALANCE ASSESSMENT 
2.6.1 Standing Balance Protocol 
Each participant underwent 12 trials in the standing balance protocol. For the first six trials, 
participants were instructed to stand on the right embedded forceplate with their eyes open (EO), 
feet side-by-side and completely touching, and remain still for 60 seconds. As described 
previously, the first trial was NT while the second and third were randomized to F then B or B 
then F. This same order of trials was repeated for trials four through six. For the second half of 
the 12 trials, participants were instructed to stand on the right embedded forceplate with their 
eyes closed (EC) feet side-by-side and completely touching, and remain still for 60 seconds. The 
cognitive conditions were repeated in the same order as done in the previous trials with EO.  
2.6.2 Standing Balance Analysis 
While all 48 participants completed the standing balance protocol, a subset of 40 participants 
was selected for analysis (Table 2) due to availability of SAA and WMH data. Of these 40, all 
were included in the analysis with SAA, 36 were included in the analysis with WMH ALL and 
 29 
the individual WMH tracts (Table 3), and 21 were included in the analysis with CHOL and 
NON-CHOL (Table 4). 
   
Table 2: Standing balance participant characteristics for overall analysis and analysis of SAA 
(n=40) including mean, (SD), [range] 
 
Age [years] Height [m] Weight [kg] 
75.6 
(4.06) 
[70.3-83.5] 
1.69 
(0.09) 
[1.53-1.87] 
75.9 
(14.9) 
[47.4-119.6] 
 
 
 
Table 3: Standing balance participant characteristics for analysis of WMH ALL and individual 
WMH Tracts (n=36) including mean, (SD), [range] 
 
Age [years] Height [m] Weight [kg] 
75.2 
(3.95) 
[70.6-83.4] 
1.69 
(0.08) 
[1.53-1.87] 
76.2 
(12.5) 
[55.6-107.5] 
 
 
 
Table 4: Standing balance participant characteristics for analysis of CHOL and NON-CHOL 
tracts (n=21) including mean, (SD), [range] 
Age [years] Height [m] Weight [kg] 
74.6 
(3.42) 
[70.6-83.3] 
1.69 
(0.08) 
[1.53-1.87] 
75.4 
(12.8) 
[55.6-102] 
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The raw digital output collected by the forceplate was imported into MATLAB (R2010a, 
MathWorks, Natick, MA) for all analyses. Center of pressure in the medial-lateral (ML) 
direction (COPML) and center of pressure in the anterior-posterior (AP) direction (COPAP) were 
first calculated over the entire trial from the raw data using the following formulas: 
 
 
 
In these formulas, i is the individual frame number, H is the height difference from the 
floor surface to the forceplate, FX is the force in the x-direction, FY is the force in the y-
direction, FZ is the force in the z-direction, and MY is the moment generated about the y-axis. 
Center of pressure in each direction was zero meaned by subtracting the average center of 
pressure for the entire trial from the center of pressure at each point in time. The zero meaned 
data was filtered using an eighth order Butterworth filter with cut-off frequency of 1.5 Hz and 
downsampled to 120 Hz.  
The standard deviations of both COPML and COPAP (ML RMS and AP RMS, 
respectively) were calculated using the following formulas (Maurer & Peterka, 2005): 
 
 
 
The mean sway velocity of both COPML and COPAP (ML VEL and AP VEL, 
respectively) were calculated using the following formulas (Maurer & Peterka, 2005): 
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Finally, the distance covered by the center of pressure in both directions or the total 
change in resultant center of pressure (PL) was calculated and time normalized using the 
following formula (Kim et al., 2009): 
 
 
 
Only the second trial within each condition was used for analysis in order to eliminate 
any practice effects seen in the first trial. The statistical analysis consisted of two parts. First, we 
determined the effect of eye and task conditions on standing balance by fitting a mixed linear 
model. The analysis was done using subject as a random effect and fixed effects of eye 
condition, task condition, and the interaction of the two. The dependent variables included AP 
RMS, ML RMS, PL, AP VEL, and ML VEL and were each considered individually. Statistical 
significance was set at 0.05. Graphically, the relationship of the balance outcome measures and 
predictor variables SAA, WMH ALL, AACC, CC, and SS appeared non-linear. The second 
analysis was performed to explore this non-linear relationship between the outcome balance 
measures and the predictor variables. We computed the Spearman rank correlation coefficient (ρ) 
within each task and eye condition between each standing balance variable and the predictor 
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variables. The dependent variables were AP RMS, ML RMS, PL, AP VEL, and ML VEL. The 
independent variables were SAA, WMH ALL, AACC, CC, SS, CHOL, and NON-CHOL. 
Statistical significance was again set at 0.05. This correlation analysis was repeated with the 
addition of average gait speed from the NT gait trial from each subject as a controlling variable 
to obtain partial correlation coefficients. With this addition, the analysis was done to look at the 
relationship of the balance outcome measures to the predictor variables while controlling for gait 
speed. This can be interpreted as controlling for overall health status. Statistical significance 
remained at 0.05. All statistical analyses were conducted using SAS® version 9.2 (SAS Institute 
Inc., Cary, NC).    
2.7 GAIT ASSESSMENT 
2.7.1 Gait Protocol 
Each participant underwent six gait trials. Participants were asked to walk at a self-selected pace 
around an outlined oval-shaped track for 60 seconds with their eyes open (Figure 5). Participants 
averaged 5 complete laps around the track. With regards to cognitive tasks, the first trial was NT 
while the second and third were randomized to F then B or B then F. This same order of trials 
was repeated for trials four through six. Footswitch and Vicon motion capture data were 
collected during the entire trial; however, the data captured only over the straightaways were 
processed. It was assumed that after elimination of the curves from the data that the participant 
was considered to be continuously walking and that data from the individual passes could be 
merged into one larger trial for analysis.  
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Figure 5: Circular track set-up and distance traveled for each straightaway. Only data collected 
on the straightaways (indicated by green check marks) were processed. 
 
2.7.2 Gait Analysis 
While all 48 participants completed the gait protocol, a subset of 41 participants was selected for 
analysis (Table 5) due to the availability of SAA and WMH data. Of these 41, 40 were included 
in the analysis with SAA (Table 6), 34 were included in the analysis with WMH ALL and the 
individual WMH tracts (Table 7), and 20 were included in the analysis with CHOL and NON-
CHOL (Table 8). 
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Table 5: Gait participant characteristics for overall analysis (n=41) including mean, (SD), 
[range] 
 
Age [years] Height [m] Weight [kg] 
75.5 
(3.89) 
[70.6-83.5] 
1.68 
(0.091) 
[1.52-1.87] 
76.9 
(14.8) 
[47.4-119.6] 
 
 
 
Table 6: Gait participant characteristics for analysis of SAA (n=40) including mean, (SD), 
[range] 
 
Age [years] Height [m] Weight [kg] 
75.6 
(3.89) 
[70.3-83.5] 
1.68 
(0.09) 
[1.52-1.87] 
76.2 
(15.1) 
[47.4-119.6] 
 
 
 
Table 7: Gait participant characteristics for analysis of WMH ALL and individual WMH tracts 
(n=34) including mean, (SD), [range] 
 
Age [years] Height [m] Weight [kg] 
75.2 
(3.7) 
[70.6-83.4] 
1.67 
(0.09) 
[1.52-1.87] 
76.7 
(12.2) 
[55.6-107.5] 
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Table 8: Gait participant characteristics for analysis of CHOL and NON-CHOL tracts (n=20) 
including mean, (SD), [range] 
 
Age [years] Height [m] Weight [kg] 
75.4 
(3.52) 
[70.6-83.3] 
1.67 
(0.09) 
[1.52-1.87] 
75.5 
(12.7) 
[55.6-102] 
 
 
Using the Vicon motion capture video output, frame ranges were identified as to when 
the participant was walking across the straightaways of the track so that marker and footswitch 
data were analyzed only over those particular frames. One straightaway frame range was referred 
to as one pass. For each pass, the sternum marker was identified and labeled from the 
reconstructed trajectories from the Vicon motion capture data. The trajectory of the sternum in 
the Y direction (STRNY) was then exported to calculate gait speed in MATLAB. The raw digital 
footswitch signal collected by the Bluetooth receiver was imported into MATLAB. Using a 
custom MATLAB code, heel contact and toe off were temporally identified over the designated 
frame ranges for each pass. Heel contact was identified as the temporal location of the rising 
edge of the right and left heel switch voltages. Toe off was identified as the temporal location of 
the falling edge of the right and left toe switch voltages (Figure 6).  
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Figure 6: Typical output for one pass showing both left and right heel and toe switches. Heel 
contact is identified as the rising edge of the voltage from the heel switch. Toe off is identified as 
the falling edge of the voltage from the toe switch. 
 
Using MATLAB, gait speed (GS), or the velocity in the direction of travel, was 
calculated. For each pass, continuous gait speed was calculated over the entire duration using the 
following formula: 
 
 
 
Using an interclass correlation (ICC) on a sub-set of average gait speeds from 10 
participants with 12 passes, it was statistically demonstrated that after the first six passes, gait 
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speed stabilized and the ICC was 0.90. With this, the average gait speed (Average GS) for each 
participant for each trial type was defined as the average gait speed over the first six passes per 
trial.  
The standard deviation of several temporal gait parameters was calculated across all 
passes for each trial using the heel contact and toe off values determined from the footswitch 
data. These variables included stance time variability in milliseconds (STV), double support time 
variability in milliseconds (DSV), step time variability in milliseconds (SEV), and cadence 
variability in steps per minute (CV). Stance time was defined as the time from heel contact to toe 
off of the same foot or the time spent with each foot completely on the ground. Double support 
time was defined as the time from toe off of one foot to the next heel contact of the other foot or 
the time spent when both feet are on the ground. Step time was defined as the time from heel 
contact of one foot to the next heel contact of the other foot or the time between stepping with 
one foot and stepping with the next. Cadence was defined as the number of steps taken per 
minute. The variables were calculated for both the left and right feet and averaged across both 
sides under the assumption that gait was symmetrical.  
As in the statistical analysis for standing balance, only the second trial within each 
condition was used to eliminate any practice effects seen in the first trial. The statistical analysis 
consisted of three parts. First, we determined the effect of task conditions on temporal variability 
by fitting a linear mixed model. The analysis was done using subject as a random effect and task 
condition as a fixed effect. The dependent variables included Average GS, STV, DSV, SEV, and 
CAD and were each considered individually. Statistical significance was set at 0.05. Graphically, 
the relationship of the temporal variability measures and predictor variables SAA, WMH ALL, 
AACC, CC, and SS appeared linear. The second analysis was used to explore this linear 
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relationship between the temporal variability measures and the predictor variables. We computed 
the Pearson correlation coefficient (r) within each task between each temporal variability 
measure and the predictor variables. The dependent variables were Average GS, STV, DSV, 
SEV and CAD. The independent variables were SAA, WMH ALL, AACC, CC, SS, CHOL, and 
NON-CHOL. Statistical significance was again set at 0.05. This correlation analysis was run a 
second time but with the addition of average gait speed from each gait trial from each subject as 
a partial correlation variable. With this addition, the analysis was done to look at the relationship 
of the temporal variability measures to the predictor variables while controlling for gait speed. 
This can be interpreted as controlling for overall health status. Statistical significance remained 
set at 0.05. Since we were controlling for gait speed, this analysis was not conducted on average 
GS.  
The final analysis was conducted to determine the proportion of variability in the 
temporal variability measures explained by the predictor variables in addition to that explained 
by average GS within each task. First, temporal variability measures were regressed on average 
GS and each predictor variable individually and then simultaneously in different regression 
models. Each model’s R2 was then examined to quantify the average GS contributions alone (A), 
each predictor variable’s contribution alone (B), and the simultaneous contribution of average 
GS and each predictor variable (C). By calculating the difference between model A and C (C-A), 
the added value of each predictor variable to explaining the variability in temporal variability 
above and beyond that by average GS was determined. To determine the statistical significance 
of the R2 difference, a nested models F-test was performed. Statistical significance was held at 
0.05. All statistical analyses were conducted using SAS® version 9.2 (SAS Institute Inc., Cary, 
NC). 
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3.0  RESULTS 
3.1 STANDING BALANCE 
3.1.1 Characteristics of Independent Predictor Variables 
Within the overall standing balance analysis, three different analysis groups were defined to 
include SAA, CHOL and NON-CHOL, and WMH. Table 9 provides the summary statistics of 
each independent variable of interest to better understand the dataset used for analysis. All 
variables pertaining to WM are shown as percentages of total brain volume.  
 
Table 9: Summary statistics for independent variables used in standing balance analysis 
 
Independent Variable [units] Mean SD Range 
SAA [pmole mL atropine equivalent-1] 0.54 0.61 0-2.05 
CHOL [% Total Brain Volume] 0.000656 0.000615 0-0.00177 
NON-CHOL [% Total Brain Volume] 0.00999 0.0109 0.000251-0.0320 
WMH ALL [% Total Brain Volume] 0.104 0.0974 0.00219-0.542 
AACC [% Total Brain Volume] 0.0582 0.0466 0-0.215 
CC [% Total Brain Volume] 0.0362 0.0332 0-0.135 
SS [% Total Brain Volume] 0.00342 0.000861 0-0.0595 
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3.1.2 Effect of Vision and Dual-Task on Standing Balance 
The effect of standing with both EO and EC was investigated for all subjects within each 
analysis group through the use of a mixed linear regression model. As expected, eye condition 
was significant across all subjects with p<0.0001 for all COP variables of interest. In addition to 
eye condition, the effect of performing a dual-task while standing was also investigated, and 
surprisingly, task effects were only revealed in five of the fifteen dependent variables analyzed. 
The interaction effect of eye and task condition did not reveal any significance. The p-values for 
all effects and results of the post-hoc analysis for the task effect are presented in Table 10 with 
statistical significance indicated by an asterisk.   
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Table 10: Statistical analysis of all dependent COP variables to determine task and eye condition 
effects. p-values are provided (α=0.05). Significance is denoted by an asterisk (*). 
 
COP 
Variable 
Analysis Group Eye Condition Task Task 
Post-hoc 
Interaction 
AP RMS SAA <0.0001 * 0.011 * NT/F 0.54 
ML RMS SAA <0.0001 * 0.15  0.82 
PL SAA <0.0001 * 0.049 * NT/B 0.57 
AP VEL SAA <0.0001 * 0.025 NT/B 0.55 
ML VEL SAA <0.0001 * 0.23  0.67 
 
AP RMS CHOL/NON-CHOL <0.0001 * 0.025 * NT/F 0.37 
ML RMS CHOL/NON-CHOL <0.0001 * 0.058  0.92 
PL CHOL/NON-CHOL <0.0001 * 0.54  0.33 
AP VEL CHOL/ NON-CHOL <0.0001 * 0.12  0.55 
ML VEL CHOL/ NON-CHOL <0.0001 * 0.81  0.31 
 
AP RMS WMH <0.0001 * 0.064  0.45 
ML RMS WMH <0.0001 * 0.36  0.74 
PL WMH <0.0001 *  0.083  0.34 
AP VEL WMH <0.0001 * 0.043 * NT/B 0.51 
ML VEL WMH <0.0001 * 0.26  0.29 
 
 
These effects are further demonstrated graphically in Figures 7, 8, and 9. Across all 
analyses, the dependent variables of interest increase significantly when participants stand with 
EC compared to EO.  
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Figure 7: Averaged COP variables across each task for EO and EC for SAA cohort. EO 
is represented by the three bars on the left while EC is represented by the three bars on the right. 
Eye condition was significant for all variables of interest. Standard error bars are shown. 
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Figure 8: Averaged COP variables across each task for EO and EC for CHOL and NON-CHOL 
cohort. EO is represented by the three bars on the left while EC is represented by the three bars 
on the right. Eye condition was significant for all variables of interest. Standard error bars are 
shown. 
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Figure 9: Averaged COP variables across each task for EO and EC for WMH ALL and 
individual tract cohort. EO is represented by the three bars on the left while EC is represented by 
the three bars on the right. Eye condition was significant for all variables of interest. Standard 
error bars are shown. 
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3.1.3 Standing Balance and SAA 
Using the Spearman correlation coefficient, the non-linear relationship between the outcome 
balance measures and SAA was examined. This was done across all three tasks and both eye 
conditions. There were no significant relationships between these variables. The Spearman 
coefficients and corresponding p-values are presented in the appendix, Table 17. The same 
relationship between the COP variables of interest and SAA was reanalyzed to better understand 
if the differences in balance outcome measures were due to overall health. This was done by 
adjusting for gait speed within the statistical model. The average GS during the first NT gait trial 
was used.  Again, there were no significant relationships between these variables. The adjusted 
Spearman rank correlation coefficients and their corresponding p-values are presented in the 
appendix, Table 17. 
3.1.4 Standing Balance and WMH 
The Spearman rank correlation coefficient was again utilized to describe the relationship 
between the outcome balance variables of interest and WMH ALL, AACC, CC, and SS. 
Significant relationships were seen when participants did not perform a dual-task and had their 
eyes closed. With EC, significant relationships existed between standing balance and WMH 
ALL, AACC and CC. There were no significant relationships during any of the tasks with EO or 
F or B dual-task conditions with EC. The Spearman correlation coefficients for the NT condition 
under EC for select predictor variables and balance outcome measures are shown in Table 11. 
All Spearman correlation coefficients are presented in the appendix, Table 17. A positive 
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correlation coefficient indicates an increase in the balance sway measure with an increase in the 
predictor variable. All significant findings demonstrated this relationship. 
 
 
Table 11: Unadjusted Spearman rank correlation coefficients and their corresponding p-values 
describing the relationship between the COP variables of interest and WMH ALL, AACC, and 
CC (α=0.05) for EC conditions without a dual-task. Significance is denoted by an asterisk (*). 
 
COP 
Variable 
Predictor 
Variable 
Eye  
Condition 
Task  
Condition 
Spearman  
Coefficient 
p-value 
AP RMS AACC EC NT 0.23 0.18 
ML RMS AACC EC NT 0.34 0.045 * 
ML VEL AACC EC NT 0.17 0.31 
      
AP RMS CC EC NT 0.19 0.27 
ML RMS CC EC NT 0.45 0.0057 * 
ML VEL CC EC NT 0.38 0.022 * 
 
 
The same relationship between the COP variables of interest and WMH ALL, AACC, 
CC, and SS was reanalyzed to investigate if the differences in balance outcome measures were 
attributed to overall health by adjusting for gait speed within the statistical model. There were 
significant relationships seen in both eye conditions when not performing a task. Additionally, 
significant relationships were also seen when participants stood with their eyes closed with F 
task. The Spearman correlation coefficients for the NT condition under both EO and EC and for 
the F condition under EC for select predictor variables and outcome measures are shown in 
Table 12. All adjusted Spearman correlation coefficients are presented in the appendix, Table 17. 
Again, all significant findings demonstrated a positive relationship. 
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Table 12: Adjusted Spearman rank correlation coefficients and their corresponding p-values 
describing the relationship between the COP variables of interest and WMH ALL, AACC, SS, 
and CC (α=0.05) for EC and EO conditions without a dual-task and EC with a F task. 
Significance is denoted by an asterisk (*). 
 
COP 
Variable 
Predictor 
Variable 
Eye  
Condition 
Task  
Condition 
Spearman  
Coefficient 
p-value 
AP RMS WMH ALL EC NT 0.36 0.0337 * 
ML RMS WMH ALL EC NT 0.45 0.0063 * 
ML VEL WMH ALL EC NT 0.29 0.085 
      
AP RMS AACC EC NT 0.24 0.18 
ML RMS AACC EC NT 0.39 0.022 * 
ML VEL AACC EC NT 0.23 0.20 
      
AP RMS CC EC NT 0.22 0.21 
ML RMS CC EC NT 0.51 0.0023 * 
ML VEL CC EC NT 0.44 0.012 * 
      
AP RMS SS EC NT 0.46 0.0061 * 
ML RMS SS EC NT 0.23 0.19 
ML VEL SS EC NT 0.269 0.12 
      
AP RMS WMH ALL EC F 0.37 0.031 * 
ML RMS WMH ALL EC F 0.16 0.35 
ML VEL WMH ALL EC F 0.16 0.35 
      
AP RMS CC EC F 0.39 0.023 * 
ML RMS CC EC F 0.27 0.12 
ML VEL CC EC F 0.28 0.10 
      
AP RMS SS EC F 0.29 0.086 
ML RMS SS EC F 0.35 0.041 * 
ML VEL SS EC F 0.21 0.23 
      
AP RMS CC EO NT 0.38 0.026 * 
ML RMS CC EO NT 0.22 0.21 
ML VEL CC EO NT 0.35 0.041 * 
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Figures 10-13 further demonstrate the significant relationships between two of the 
balance measures and the corresponding predictor variables.  
 
 
 
 
Figure 10: ML RMS [mm] vs. WMH ALL [% Total Brain Volume] under the NT, EC 
condition. The relationship between these two variables is significant with a Spearman rank 
correlation coefficient of 0.45 and p=0.0063. With a positive correlation, as the overall WMH for 
all tracts increases, ML RMS also increases.  
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Figure 11: ML RMS [mm] vs. AACC [% Total Brain Volume] under the NT, EC condition. The 
relationship between these two variables is significant with a Spearman rank correlation 
coefficient of 0.39 and p=0.022. With a positive correlation, as AACC increases, ML RMS also 
increases. 
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Figure 12: ML RMS [mm] vs. CC [% Total Brain Volume] under the NT, EC condition. The 
relationship between these two variables is significant with a Spearman rank correlation 
coefficient of 0.51 and p=0.0023. With a positive correlation, as CC increases, ML RMS also 
increases. 
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Figure 13: ML VEL [mm s-1] vs. CC [% Total Brain Volume] under the NT, EC condition. The 
relationship between these two variables is significant with a Spearman rank correlation 
coefficient of 0.44 and p=0.012. With a positive correlation, as CC increases, ML VEL also 
increases. 
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3.1.5 Standing Balance, CHOL, and NON-CHOL 
Finally, the Spearman rank correlation coefficient was used to determine the non-linear 
relationship between the outcome balance measures and CHOL and NON-CHOL across all three 
tasks and both eye conditions. There were no significant relationships between these variables. 
The Spearman coefficients and corresponding p-values are presented in the appendix, Table 17. 
The same relationships were reanalyzed to better understand if the difference in balance outcome 
measures was due to overall health by adjusting for gait speed within the statistical model. 
Again, there were no significant relationships between these variables. The adjusted Spearman 
correlation coefficients and their corresponding p-values are presented in the appendix, Table 17. 
3.2 GAIT 
3.2.1 Characteristics of Independent Predictor Variables 
As with the standing balance analysis, three different groups were defined to include SAA, 
CHOL and NON-CHOL, and WMH. Table 13 provides the summary statistics of each 
independent variable of interest to better understand the dataset used for analysis. All variables 
pertaining to WM are shown as percentages of total brain volume.  
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Table 13: Summary statistics for independent variables used in gait analysis. 
 
Independent Variable [units] Mean SD Range 
SAA [pmole mL atropine equivalent-1] 0.50 0.62 0-2.05 
CHOL [% Total Brain Volume] 0.000734 0.000678 0-0.00214 
NON-CHOL [% Total Brain Volume] 0.0108 0.0109 0.00145-0.0319 
WMH ALL [% Total Brain Volume] 0.112 0.104 0.00555-0.452 
AACC [% Total Brain Volume] 0.0673 0.0478 0.00502-0.215 
CC [% Total Brain Volume] 0.0395 0.0343 0-0.135 
SS [% Total Brain Volume] 0.00391 0.00812 0-0.0364 
 
3.2.2 Effects of Dual-Task on Gait 
The effect of walking while performing a dual-task was investigated for all subjects within each 
analysis group through the use of a mixed linear regression model. A significant task effect was 
seen in all but two variables of interest. The p-values for task effects and results of the post-hoc 
analysis are presented in Table 14 with statistical significance indicated by an asterisk.    
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Table 14: Statistical analysis of all dependent gait variables of interest to determine task 
condition effects during gait (α=0.05). p-values are provided. Post-hoc results indicate which 
tasks were significantly different. Significance denoted by asterisk (*). 
 
Gait Variable Analysis Group Task Task Post-hoc 
CV SAA 0.0044 * NT/F, NT/B 
DSV SAA 0.041 * NT/B 
STV SAA 0.0002 * NT/B 
SEV SAA 0.011 * NT/F, NT/B 
Average GS SAA <0.0001 * NT/F, NT/B, F/B 
 
CV CHOL/NON-CHOL 0.120  
DSV CHOL/NON-CHOL 0.60  
STV CHOL/NON-CHOL 0.0013 * NT/B, F/B 
SEV CHOL/NON-CHOL 0.011 * NT/F, NT/B 
Average GS CHOL/NON-CHOL <0.0001 * NT/F, NT/B, F/B 
 
CV WMH 0.0063 * NT/F, NT/B 
DSV WMH 0.048 * NT/B 
STV WMH 0.0007 * NT/F, NT/B 
SEV WMH 0.015 * NT/F, NT/B 
Average GS WMH <0.0001 * NT/F, NT/B, F/B 
 
 
These effects are further demonstrated graphically in Figures 14-18. For average GS, 
there is a significant decrease in GS between walking without a task and walking with a task. 
Additionally, there is a significant decrease in GS when walking between B and F. This was 
consistent across all analyses. For the SAA analysis, stance time and double support variability 
increased significantly between the NT and B conditions. Step time and cadence variability also 
increased significantly between the NT and B conditions but also increased significantly between 
the NT and F conditions. Across all variables, there was no significant difference between the F 
and B conditions. For the CHOL and NON-CHOL analysis, double support and cadence 
variability did not show any differences between tasks. Stance time variability showed a 
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significant increase in variability between NT and B and also between F and B. Step time 
variability showed increased variability between NT and F and NT and B. Finally, for the WMH 
analysis, stance time, step time, and cadence variability all showed a significant increase in 
variability between NT and F and NT and B. Double support time variability only showed a 
significant increase in variability between NT and B. Across all variables, there was no 
significant difference between the F and B conditions.  
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Figure 14: Average gait speed [m s-1] across tasks for SAA analysis (top left), CHOL and NON-
CHOL (top right), and WMH (bottom middle). Asterisk (*) indicates statistical significance 
between tasks. Standard error bars are shown. 
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Figure 15: Average stance time variability [ms] across tasks for SAA analysis (top left), CHOL 
and NON-CHOL (top right), and WMH (bottom middle). Asterisk (*) indicates statistical 
significance between tasks. Standard error bars are shown. 
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Figure 16: Average double support time variability [ms] across tasks for SAA analysis (top left), 
CHOL and NON-CHOL (top right), and WMH (bottom middle). Asterisk (*) indicates statistical 
significance between tasks. Standard error bars are shown. 
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Figure 17: Average step time variability [ms] across tasks for SAA analysis (top left), CHOL 
and NON-CHOL (top right), and WMH (bottom middle). Asterisk (*) indicates statistical 
significance between tasks. Standard error bars are shown. 
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Figure 18: Average cadence variability [steps min-1] across tasks for SAA analysis (top left), 
CHOL and NON-CHOL (top right), and WMH (bottom middle). Asterisk (*) indicates statistical 
significance between tasks. Standard error bars are shown. 
 
 
 
 
 
 
 
 61 
3.2.3 Relationship between Gait Variability and the Predictor Variables 
The relationship between the measures of gait variability and the predictor variables of interest 
was determined using the linear Pearson correlation coefficient. First, this analysis was done on 
average GS and the temporal variability parameters calculated across all task types. Average GS 
was not correlated with any of the predictor variables of interest across all tasks. However, it was 
determined that there was a positive, significant relationship between cadence variability and 
NON-CHOL without a dual-task, stance time variability and NON-CHOL without a dual-task, 
and step time variability and NON-CHOL without a dual-task or under the B condition. The 
relationship between the measures of gait variability and the predictor variables was again 
conducted but by adjusting for gait speed within the linear model. By adjusting for gait speed, it 
could be inferred if the differences in gait variability were due to health status. The average GS 
corresponding to the task of interest was used for each analysis. After adjusting for gait speed, 
there was again a positive significant relationship between cadence variability and NON-CHOL 
without a dual-task, stance time variability and NON-CHOL without a dual-task, and step time 
variability and NON-CHOL under the B condition. Additionally, stance time variability was also 
significantly related to SS under the F condition and step time variability was no longer related to 
NON-CHOL without a dual-task condition. As in standing balance, a positive correlation 
indicated an increase in gait variability with an increase in the predictor variables. The Pearson 
correlation coefficients and their associated p-values for both the unadjusted and adjusted 
analyses are presented in Table 15 for the significant conditions. All adjusted and unadjusted 
Pearson correlation coefficients are presented in the appendix, Table 18. 
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Table 15: Unadjusted and adjusted Pearson correlation coefficients and their corresponding p-
values describing the relationship between the gait variability variables of interest and NON-
CHOL and SS (α=0.05) for all tasks. Significance is denoted by an asterisk (*). 
 
Task Variability Measure 
Predictor 
Variable 
Unadjusted 
Pearson 
Coefficient 
Unadjusted 
Pearson 
p-value 
Adjusted 
Pearson 
Coefficient 
Adjusted 
Pearson 
p-value 
NT CV NON-CHOL 0.56 0.01 * 0.56 0.012 * 
NT CV SS 0.095 0.61 0.096 0.61 
F CV NON-CHOL -0.024 0.91 -0.027 0.91 
F CV SS 0.037 0.84 0.039 0.83 
B CV NON-CHOL 0.16 0.49 0.19 0.45 
B CV SS 0.042 0.82 0.046 0.81 
 
NT STV NON-CHOL 0.58 0.0075 * 0.57 0.010 * 
NT STV SS 0.053 0.77 0.077 0.68 
F STV NON-CHOL 0.046 0.85 -0.046 0.85 
F STV SS 0.32 0.070 0.37 0.038 * 
B STV NON-CHOL 0.35 0.13 0.26 0.29 
B STV SS 0.023 0.89 0.051 0.79 
 
NT SEV NON-CHOL 0.49 0.027 * 0.45 0.051 
NT SEV SS 0.12 0.49 0.15 0.43 
F SEV NON-CHOL 0.10 0.67 0.010 0.97 
F SEV SS 0.21 0.25 0.250 0.18 
B SEV NON-CHOL 0.59 0.0088 * 0.54 0.021 * 
B SEV SS 0.18 0.34 0.23 0.21 
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Figures 19-22 further graphically demonstrate the significant relationships between three 
of the gait variability measures and the NON-CHOL during NT and B.  
 
 
 
 
Figure 19: CV [steps min-1] vs. NON-CHOL [% Total Brain Volume] during NT. The 
relationship between these two variables is significant with a Pearson correlation coefficient of 
0.56 and p=0.01. With a positive correlation, as NON-CHOL increases, CV also increases. 
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Figure 20: STV [ms] vs. NON-CHOL [% Total Brain Volume] during NT. The relationship 
between these two variables is significant with a Pearson correlation coefficient of 0.57 and 
p=0.0075. With a positive correlation, as NON-CHOL increases, STV also increases. 
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Figure 21: SEV [ms] vs. NON-CHOL [% Total Brain Volume] during NT. The relationship 
between these two variables is significant with a Pearson correlation coefficient of 0.49 and 
p=0.027. With a positive correlation, as NON-CHOL increases, SEV also increases. 
  
 
 
 
 
 
 66 
 
 
Figure 22: SEV [ms] vs. NON-CHOL [% Total Brain Volume] during B. The 
relationship between these two variables is significant with a Pearson correlation coefficient of 
0.59 and p=0.0088. With a positive correlation, as NON-CHOL increases, SEV also increases. 
3.2.4 Explanation of Gait Variability by Predictor Variables and Gait Speed 
As mentioned previously, regression analyses were used to determine the contributions of both 
the predictor variables and gait speed to the explanation of gait variability. By using the R2 
difference between the first model with average GS only and the third model with the predictor 
variable of interest and average GS, the added value of the predictor variable could be quantified. 
With regards to cadence, regression analyses revealed that when experiencing the NT condition, 
NON-CHOL explained over 32% of the variability above and beyond that explained by average 
GS. With regards to double support, regression analyses demonstrated that under the NT 
condition, NON-CHOL, SAA, WMH ALL, and CC all significantly contributed to the 
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explanation of the variability in double support time above and beyond that explained by average 
GS with NON-CHOL explaining the most at 9%. All predictor variables showed a significant 
contribution to stance time variability under NT with NON-CHOL most notably accounting for 
21% of the variability above that explained by gait speed. All but CHOL and NON-CHOL were 
also significant for stance time variability under the F condition and all but CHOL were 
significant for stance time variability under the B condition. Finally, when looking at step time 
variability, all predictor variables except for CHOL showed a significant contribution when not 
experiencing a dual-task or under the B condition. When not given a task, NON-CHOL 
explained 16% of the step time variability above beyond that explained by gait speed while when 
given a B task, NON-CHOL explained 24%. Under the F condition, all predictor variables other 
than CHOL and NON-CHOL showed significant contributions. Interestingly, across all tasks and 
gait variability measures, NON-CHOL seemed to account for the most variability in gait 
variability measures above and beyond that explained by gait speed.  The significant variables of 
interest are presented in Table 16 while all values for the complete regression analysis are 
presented in the appendix, Table 19.  
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Table 16: R2 values obtained by regressing each gait variability measure on average GS alone 
(A), each predictor variable alone (B), and on average GS and each predictor variable combined 
(C). The added value of each predictor variable is quantified using the R2 difference between 
models C and A. Statistical significance of the combined effects was set at α=0.05 and is denoted 
by an asterisk (*). 
 
Task Variability Measure 
Predictor 
Variable 
GS 
Only 
(A) 
Predictor  
Only (B) 
GS & 
Predictor 
(C) 
Δ R2  
(C-A) 
p-value 
of Δ R2 
NT CV NON-CHOL 0.0037 0.32 0.32 0.32 0.038 * 
 
NT DSV NON-CHOL 0.22 0.16 0.31 0.09 0.042 * 
NT DSV SAA 0.22 0.0036 0.25 0.03 0.0054 * 
NT DSV WMH ALL 0.15 0.028 0.20 0.05 0.0337 * 
NT DSV CC 0.15 0.033 0.21 0.06 0.026 * 
 
NT STV CHOL 0.35 0.0055 0.35 0 0.024 * 
NT STV NON-CHOL 0.35 0.33 0.56 0.21 0.0009 * 
NT STV SAA 0.41 0.0091 0.42 0.01 <0.0001 * 
NT STV WMH ALL 0.38 0.019 0.42 0.04 0.0002 * 
NT STV AACC 0.38 0.001 0.40 0.02 0.0004 * 
NT STV CC 0.38 0.0088 0.41 0.03 0.0003 * 
NT STV SS 0.35 0.0028 0.36 0.01 0.0016 * 
F STV SAA 0.26 0.077 0.30 0.04 0.0015 * 
F STV WMH ALL 0.20 0.0021 0.21 0.01 0.028 * 
F STV AACC 0.20 0.0001 0.21 0.01 0.028 * 
F STV CC 0.20 0.0027 0.21 0.01 0.025 * 
F STV SS 0.21 0.11 0.32 0.11 0.0037 * 
B STV NON-CHOL 0.26 0.12 0.31 0.05 0.045  * 
B STV SAA 0.32 0.0002 0.33 0.01 0.0007 * 
B STV WMH ALL 0.32 0.016 0.36 0.04 0.001 * 
B STV AACC 0.32 0 0.34 0.02 0.0018 * 
B STV CC 0.32 0.033 0.38 0.06 0.0005 * 
B STV SS 0.33 0.0005 0.33 0 0.0027 * 
 
NT SEV NON-CHOL 0.21 0.24 0.37 0.16 0.019 * 
NT SEV SAA 0.25 0.006 0.25 0 0.0053 * 
NT SEV WMH ALL 0.23 0.0075 0.24 0.01 0.013 * 
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Table 16 (continued) 
 
NT SEV AACC 0.23 0.001 0.23 0 0.018 * 
NT SEV CC 0.23 0.0052 0.25 0.02 0.013 * 
NT SEV SS 0.21 0.015 0.23 0.02 0.023 * 
F SEV SAA 0.20 0.030 0.21 0.01 0.014 * 
F SEV WMH ALL 0.18 0.0022 0.18 0 0.047 * 
F SEV AACC 0.18 0.0027 0.19 0 0.046 * 
F SEV CC 0.18 0.0041 0.18 0 0.047 * 
F SEV SS 0.21 0.046 0.26 0.05 0.015 * 
B SEV NON-CHOL 0.19 0.34 0.43 0.24 0.012 * 
B SEV SAA 0.21 0.012 0.24 0.03 0.0077 * 
B SEV WMH ALL 0.25 0.0097 0.28 0.03 0.0075 * 
B SEV AACC 0.25 0 0.27 0.02 0.0099 * 
B SEV CC 0.25 0.0049 0.27 0.02 0.0088 * 
B SEV SS 0.29 0.032 0.33 0.04 0.0036 * 
 
 
To further explain these results, two plots were generated for a select sub-set of the 
significant relationships between gait speed and the predictor variable on gait variability, and 
they can be found in figures 23-27. For all figures, the plot on the left represents the predictor 
variable plotted against average GS, demonstrating average GS’s contribution to the variability. 
The plot on the right represents the residuals of the dependent gait variability measure plotted 
against the predictor variable of interest, demonstrating the contribution of the predictor variable 
to explaining the variability in the gait measure above and beyond that explained by average GS.  
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Figure 23: On left, CV [steps min-1] vs. Average GS [m s-1] under NT condition. ΔR2=0.0037. 
On right, the average GS adjusted residuals of CV [steps min-1] are plotted against NON-CHOL 
[% Total Brain Volume] under NT condition. ΔR2=0.32. Thus, 32% of the variability in cadence 
variability is explained by NON-CHOL under NT above and beyond that explained by average 
GS. 
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Figure 24: On left, STV [ms] vs. Average GS [m s-1] under NT condition with R2=0.35. On 
right, the average GS adjusted residuals of STV [ms] are plotted against NON-CHOL [% Total 
Brain Volume] under NT condition. ΔR2=0.21. Thus, 21% of the variability in stance time 
variability is explained by NON-CHOL under NT above and beyond that explained by average 
GS. 
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Figure 25: On left, STV [ms] vs. Average GS [m s-1] under F condition with R2=0.21. On right, 
the average GS adjusted residuals of STV [ms] are plotted against SS [% Total Brain Volume] 
under F condition. ΔR2=0.11. Thus, 11% of the variability in stance time variability is explained 
by SS under F above and beyond that explained by average GS. 
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Figure 26: On left, SEV [ms] vs. Average GS [m s-1] under NT condition with R2=0.21. On 
right, the average GS adjusted residuals of SEV [ms] are plotted against NON-CHOL [% Total 
Brain Volume] under NT condition. ΔR2=0.16. Thus, 16% of the variability in step time 
variability is explained by NON-CHOL under NT above and beyond that explained by average 
GS. 
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Figure 27: On left, SEV [ms] vs. Average GS [m s-1] under B condition with R2=0.19. On right, 
the average GS adjusted residuals of SEV [ms] are plotted against NON-CHOL [% Total Brain 
Volume] under B condition. ΔR2=0.24. Thus, 24% of the variability in step time variability is 
explained by NON-CHOL under B above and beyond that explained by average GS. 
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4.0  DISCUSSION 
4.1 STANDING BALANCE 
4.1.1 Overall Balance Performance 
The first analysis conducted on the balance outcome measures involved understanding the effects 
of two different eye conditions and three different task conditions on standing balance. As 
consistent with previous research, there was an increase in sway in the ML and AP directions, 
increased speed in both directions, and increased overall distance travelled when standing with 
eyes closed compared to eyes open (Nagano et al., 2006; Prado et al., 2007; Hansson et al., 2010; 
Strang et al., 2011). However, task effects were only seen in five out of the fifteen variables 
analyzed. In general, participants swayed more and in the AP direction when not performing a 
dual-task compared to performing a F task. They also swayed faster in the AP direction when not 
performing a task compared to a B task. It was originally hypothesized that balance performance 
would decrease (i.e. increased sway, velocity, and distance) when performing a cognitive 
challenge task due to the added attention demands required to perform both tasks. These results 
do not support this hypothesis. Previous research demonstrates conflicting results. When 
performing a visual dual-task, the amount and velocity of sway decreased in older adults 
according to Prado and colleagues (2007). According to Shumway-Cook and Woollacott (2000), 
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during a cognitively challenging auditory task, there were no significant changes in balance 
outcome measures in healthy older adults compared to standing balance without a task. 
However, Maylor and Wing (1996) and Teasdale and Simoneau (2001) found sway to increase 
in healthy older adults when performing a cognitive challenge task during quiet stance. The 
results of this research project and the discrepancy in previous work may reference back to the 
statement by Bloem and colleagues (2001) that older adults prioritize maintaining balance over 
successful completion of the secondary task, possibly to avoid falling. If this were true, the 
participants used in this analysis would have decreased accuracy in recalling the digits to better 
maintain balance while participants in the studies that saw increased sway and decline in balance 
would have maintained accuracy performance with the cognitive task while sacrificing balance. 
Further work must be conducted to identify if participants used for this study did in fact 
sacrifice accuracy of performance to better maintain balance. If accuracy is not found to be one 
potential cause, it may also be hypothesized that balance was quantitatively worse when not 
performing a task due to the long duration of the trial and the participant simply asked to stand as 
still as possible. Participants may have fatigued throughout the duration of each 60 second trial. 
Even though they were provided seated rest breaks as often as requested, some participants 
reported boredom over time with “just having to stand there”, which may have hindered their 
performance. Participants may also have not been focusing on balance when not performing a 
task but rather simply maintaining an upright posture, which could still result in significant sway 
outcomes. Furthermore, the limited statistical significance between tasks and the absence of any 
interaction effects of task and vision condition may further be explained by overall participant 
health. The screening process utilized to determine eligibility maintained strict requirements so 
as to not recruit participants of poor mental or physical health status. By including fit, active 
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older adults and excluding those with known conditions, the results may better reflect 
conclusions seen in younger adults. 
4.1.2 Standing Balance and SAA 
Part of the goal of Specific Aim 1 was to identify the relationship between SAA and balance 
outcome measures during single-task quiet stance and while performing a concurrent cognitive 
task under two different eye conditions. While the exact mechanism of action of SAA on causing 
a decline in balance is unknown, as previously mentioned, SAA has been linked to a decrease in 
cognitive function, attention, and processing speed. Pilot work has also demonstrated increased 
sway with increased SAA levels. Based on this prior knowledge, it was hypothesized that 
balance performance would decrease with increased levels of SAA and that this relationship 
would be enhanced when analyzed under a dual-task condition. This relationship was determined 
using the Spearman correlation coefficient. According to our results, no significant relationships 
were found between balance outcome measures and SAA, regardless of task or eye condition. 
Interestingly, out of the 30 correlations between SAA and the five balance outcome measures for 
all conditions, 26 of these correlations were negative, indicating a trend towards improved 
balance with increased SAA. In fact, the strongest negative correlation was -0.25 (ML RMS with 
EO and B) while the strongest positive correlation was only 0.097 (AP RMS with EC and NT). 
Even when accounting for overall health status by adjusting for gait speed, no significant 
relationships were found between SAA and balance outcome measures. Again, out of the 30 
correlations between SAA and the five balance outcome measures for all conditions, 26 of these 
were negative. Correlations in both directions had negligible changes with the strongest negative 
correlation decreasing to -0.24 and the strongest positive correlation increasing to 0.11. Since 
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there was no change in the results when adjusting for gait speed, it can be concluded that overall 
health condition does not affect the relationship between SAA and the outcome measures of 
standing balance regardless of task or eye condition. These results are inconsistent with the 
initial hypothesis and the previous pilot work.   
The absence of significant findings within the participants recruited for this analysis may 
be due to their overall health, cognitive status and lack of anticholinergic medication use. The 
participants included in this analysis had SAA levels averaging 0.54 pmole mL atropine 
equivalent-1 and ranging from 0-2.05 pmole mL atropine equivalent-1. This is much lower 
compared to previous literature using the same technique for quantifying SAA level. Participants 
recruited for work done by Mulsant and colleagues with age range of 71-95 years had average 
SAA levels of 1.50 pmole mL atropine equivalent-1 and ranged from 0.5-5.70 pmole mL atropine 
equivalent-1 (Mulsant et al., 2003). Participants used in work by Nebes and colleagues had an 
average age of 72.1 years and average SAA level of 1.72 pmole mL atropine equivalent-1 (Nebes 
et al., 2011). The pilot work completed prior to this study and showing a significant relationship 
to balance carried a very high average SAA level of 1.76 pmole mL atropine equivalent-1 and 
range of 1.2-2.6 pmole mL atropine equivalent-1. Even though the high end of our range is 
almost equal to that of the pilot work, only 11 of the 44 participants had SAA levels larger than 1 
pmole mL atropine equivalent-1 while 21 participants had undetectable SAA levels.  
Without a large variance of SAA levels and very few participants at moderate to higher 
levels, the participants in this work may not have experienced any negative effects or only 
experienced slight effects associated with the use of anticholinergic medications such as a 
decline in cognitive function or attention. Since dual-tasking while standing requires additional 
cognitive demands and attention (Pellecchia, 2005), it would have been expected that with 
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increased cognitive load from performing both tasks, participants at higher SAA levels would 
have seen a decline in balance due to the negative cognitive impact associated with SAA. 
Because this was not seen and the SAA levels are so low with a small variance in the participants 
used in this research, we can conclude that SAA level is not able to explain the significant 
changes seen in the participants’ balance between eye and task conditions. Again, this may be 
due to the fact that the participants recruited for this work were screened for overall health and 
free from cognitive deficits. 
4.1.3 Standing Balance and WMH 
Part of the goal of Specific Aim 2 was to investigate the relationship between WMH and balance 
during single-task quiet stance and stance performed under a dual-task for both eyes open and 
eyes closed. As with SAA, the mechanism of action is not clearly understood. Previous research 
by Sparto and colleagues (2008) is the only known work to associate WMH to quantitative 
balance measures through step initiation tasks, finding increased WMH levels to be associated 
with impaired balance. It was hypothesized that balance would decline with increased levels of 
overall WMH and increased levels of WMH in the individual tracts of interest, and that this 
relationship would be amplified when performing a task with eyes close. As with SAA, the 
relationship between balance and the WMH predictor variables was found using the Spearman 
correlation coefficient. Our results indicate that ML RMS significantly increased when standing 
with EC under NT when WMH ALL, AACC, and CC also increased. ML VEL also increased 
with increased CC during the NT, EC condition. No significant relationships were seen with EO 
or during a dual-task. The lack of EO correlations could be due to the overall decrease in balance 
performance in the participants when standing with EC compared to EO as previously described. 
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It was interesting that significant relationships were not seen with PL during these same 
correlations; however this could be due to the fact that RMS was only significant in one direction 
and PL is dependent on both the AP and ML directions. When adjusting for overall health using 
average gait speed, the only additional significant relationship was seen during EC with NT in 
AP RMS. It is very important to note that out of 120 correlations between balance outcome 
measures and WMH across all tasks and eye conditions, only five of these correlations (4.2%) 
were significant when unadjusted for gait speed and six out of 120 correlations (5%) were 
significant when adjusted for gait speed. With this, the significance in these results may actually 
be due only to chance rather than actual relationships with WMH.    
The absence of more significant findings from this analysis may again be attributed to 
overall participant health as was true with the SAA analysis. According to Debette and Marcus 
(2010), 11-21% of healthy adults have detectable WMH found on MRI at the age of 64. The 
average percent of total brain volume that contained WMH was 0.104% and ranged from 
0.00219-0.542%. The largest contribution to the total WMH from the combination of tracts used 
was from AACC which had an average of 0.0582% and range from 0-0.215%. The smallest 
contribution to the total WMH was from SS which had an average of only 0.00342% and range 
from 0-0.0595%. In fact, 14 of the 40 participants had undetectable WMH in the SS region. 
Unfortunately, these values are extremely difficult to compare to previous literature given the 
custom algorithm used to semi-automatically quantify WMH as a percentage of total brain 
volume. Most authors grade MRI based on a qualitative scale or determine WMH as a 
volumetric measurement rather than a percentage of total brain volume using a voxel count. Two 
references were found in which WMH was quantified as a percentage of total brain volume. 
First, the work of Sparto and colleagues (2008) was the only source that used the same method of 
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analyzing the participant MRI scans. The only region of interest used was AACC which had a 
range of 0.1-3.1% total brain volume in the tracts making up this region. This is much higher 
than the range found in this study with our high end range being 14 times less than their high end 
range. Second, Burton and colleagues (2006) found an overall WMH average in healthy older 
adults to be 0.4% total brain volume with a range of 0.2-1.2% total brain volume. Both the 
average value and high end range were twice that of our participant population generating higher 
WMH levels and a larger variance.  
Without a larger variance of WMH values and such low percentages of total brain 
volume, it can be inferred that balance in these participants is not impacted by WMH. With such 
a high health status for older adults and low levels of WMH, the participants in this project may 
have very limited or even no effects previously associated with WMH. For example, 
demyelination, loss of axons, gliosis, and dilation of the periventricular space have all been 
associated with WMH (Ota et al., 2010). Physiological consequences associated with these 
changes may then include neuronal slowing and delay of signal processing. Ultimately, this may 
lead to motor slowing (Murray et al., 2010). If higher levels of WMH were to be seen in this 
population and positive correlations existed, chances are quite likely that these participants 
would have experienced some form of motor slowing, thus preventing them from maintaining 
consistent upright stance. Balance maintenance is a dynamic process requiring continuous 
feedback and execution in response to changes in position within space. Damage to the areas 
such as the cortex, thalamus and basal ganglia as a result of WMH have been shown to interfere 
with motor output to the lower extremities during balance tasks (Hennerici et al. 1994; Tell et al. 
1998; Guttmann et al. 2000; Wolfson 2001). Since the regions of interest selected for this 
analysis are associated with those areas along with being linked to some aspect of motor control 
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including modulation, attention, and executive function (Sheline et al., 2008; Sparto et al., 2008; 
Duering et al., 2011), we should see the expected decline in balance if the average and variance 
of WMH as a percent of total brain volume was much larger for the participant population 
recruited, especially when standing with a dual-task. 
4.1.4 Standing Balance and the Combined Effects of SAA and WMH 
The first portion of Specific Aim 3 looked to determine if there was a relationship between 
standing balance under different task and eye conditions with the combined effects of SAA and 
WMH. This was accomplished using the volume of WMH located in the CHOL and NON-
CHOL tracts as determined by MRI. Again, CHOL are the tracts containing cholinergic fibers 
while NON-CHOL are the tracts not containing cholinergic fibers. It was hypothesized that 
participants taking anticholinergic medications who also showed the presence of WMH within 
the cholinergic tracts would have decreased balance performance, and this decrease would be 
exaggerated when standing while performing a task with eyes closed. Using the Spearman 
correlation, our results indicate that there were no significant relationships between the balance 
outcome measures and CHOL or NON-CHOL across all tasks and both eye conditions. These 
results held constant when adjusting for gait speed to control for overall health status.  
Previous research has indicated through the use of human and animal models that with 
the presence of WMH in cholinergic pathways, the susceptibility to anticholinergic effects 
becomes amplified (Flicker et al., 1992; Ray et al., 1992). This means that if a participant was to 
have WMH present within the white matter tracts containing cholinergic fibers, the effects of 
anticholinergic medications on balance and gait should be amplified. However, the results 
obtained here are not consistent with our hypothesis but are not surprising. To see results within 
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CHOL and NON-CHOL we would have expected to see more significant relationships between 
balance outcome measures and WMH since WMH is the main contribution to these tracts. 
Additionally, to obtain the correlations with CHOL, the results from correlations with SAA 
would also have to be significant. We were interested in identifying if the anticholinergic burden 
would be amplified due to WMH in this region, but without anticholinergic burden found in 
these participants, the CHOL tract properties would more reflect that of NON-CHOL since it is 
simply WMH, which did not show any significant results. It is again important to note that eight 
of the 21 participants used in this analysis had undetectable WMH in CHOL while the average 
was extremely small at 0.000656% of total brain volume. This value could almost be considered 
0%. We can conclude from this that the participants used in this analysis did not experience 
balance impairments due to the combined effects of WMH and SAA. These conclusions can be 
further strengthened by the characteristics of the population used for this work in which overall 
health status was maintained and little magnitude and variance existed in both WMH and SAA. 
4.2 GAIT 
4.2.1 Overall Gait Performance 
The first analysis executed on the spatiotemporal gait characteristics was done to understand the 
gait of the participants used in this research project and also to determine the effect of dual-
tasking on gait. When comparing average GS and the average temporal variability parameters 
within each task condition to previous literature, our results fall well within range of those values 
previously published involving gait variability in healthy, older, non-fallers (Menz et al., 2003; 
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Brach et al., 2010; Calisaya et al., 2011; Hollman et al., 2011). Using a mixed linear regression, 
the dual-task effect of spatiotemporal gait characteristics was determined. Average GS was 
significantly different between single and dual-task conditions along with a difference between 
the F and B condition. STV and DSV were significantly different between NT and B. SEV and 
DSV were significantly different between NT and B and NT and F except for DSV in the 
CHOL/NON-CHOL analysis. All parameters of interest showed a trend or significant findings 
toward decreased gait speed and increased variability when walking with a dual-task compared 
to single-task. These results are consistent with previous work demonstrating decreased gait 
speed and increased variability when walking while performing a cognitive challenge task 
(Hausdorff et al., 2003; Sheridan et al., 2003; Beauchet et al., 2005; Hollman et al., 2007). In 
fact, according to Hollman and colleagues (2007), gait variability is impacted by dual-task 
conditions even without the presence of cognitive impairment, which is indeed a characteristic of 
our participant population. 
The decrease in average GS while performing a task may be attributed to compensation 
during gait (Hollman et al., 2007). Through the use of this mechanism, participants may be able 
to maximize stability in walking by simply slowing down. By decreasing speed and creating a 
more stable environment, participants may be working to better cope with the cognitive 
challenges of the dual-task. However, a decrease in gait speed has been considered a contribution 
to falls (Luukinen et al., 1995; Cesari et al., 2005; Montero-Odasso et al., 2005). The increase in 
gait variability may be due to the interference of the task on gait due to competition of both the 
task and maintenance of consistent walking for available attention. Attention is independently 
required to perform a cognitive task and to walk under normal conditions. With a limited 
attention capacity, burdening the available resources by requiring more attention to perform 
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concurrent tasks could explain the changes seen here. Falls in older adults have been associated 
with activities requiring divided attention between two tasks such as walking while talking (The 
prevention of falls in later life, 1987; Bergland et al., 1998).  
It must be noted that instructions given to participants did not favor performance on 
either the cognitive challenge task or gait. Participants were simply instructed to walk at a 
normal pace while performing the task. While it was not directly implied that accuracy was being 
measured, it is unknown if participants favored one task over the other. Further investigations 
must be conducted to understand if participants sacrificed their gait for accurate performance on 
the task or if their gait is truly this variable when performing a task regardless of accuracy. 
Because attention is limited and two sources were competing for what was available to these 
participants, degradation in one or both may be seen (Abernethy, 1988; Pashler, 1994; Beauchet 
& Berrut, 2006). 
4.2.2 Spatiotemporal Gait Characteristics and SAA 
The second part of Specific Aim 1 was to investigate the relationship between SAA and 
spatiotemporal gait parameters during single and dual-task conditions. As mentioned previously, 
the mechanism of action of SAA to impact characteristics of gait is not well understood. 
Previous research has shown a link between increases in SAA with decreased mobility. 
However, these analyses were conducted using objective assessments such as the SPPB and the 
Health ABC performance score. While both assessments provide insight into overall health and 
mobility, the sensitivity of objective assessments may not be as adequate as the quantitative 
assessments of gait measures used here to distinguish more subtle differences in normal walking 
among older adults. For example, the SPPB looks to analyze gait performance by scoring 
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participants on walking speed over a four meter walk. While decreased gait speed during normal 
walking has been shown to increase fall risk (Luukinen et al., 1995; Cesari et al., 2005; Montero-
Odasso et al., 2005), there are a magnitude of other spatiotemporal parameters describing gait 
that have also been related to fall risk. Based on this limited prior work, it was hypothesized that 
increased levels of SAA would be related to decreased gait speed and increased temporal 
variability, especially when walking with a concurrent cognitive task.  
Two different analyses were conducted to better understand what impacts SAA may have 
on spatiotemporal characteristics of gait. First, the Pearson correlation coefficient was calculated 
between all five gait measures within all three tasks and SAA. It was determined that no 
significant relationships existed between SAA and spatiotemporal parameters of gait, regardless 
of task condition. These results remained consistent even when adjusting for average gait speed 
during the task of interest. The second analysis was conducted using the R2 difference between 
each predictor variable regressed on gait speed alone and then with both gait speed and the 
temporal variability parameter of interest. According to Kang and Dingwell (2007), gait 
variability varies with walking speed. In older adults, this poses an issue in identifying the 
underlying cause of changes, more specifically increases, in gait variability due to their typical 
decreases in walking speeds. Through the statistical model used, the data could be further 
explored to understand if the reason for changes in variability was actually due to changes in 
walking speed or some other confounding effects such as SAA level. Seven of the fifteen 
regressions involving SAA across all tasks and temporal gait parameters provided a significant 
result indicating that SAA significantly contributed to the variability in the selected parameters 
above and beyond that explained by average GS. The largest contribution of SAA was its 
contribution of 4% to the variability in stance time variability during a B task above and beyond 
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that of average GS. There were no significant findings with variability in cadence variability. 
However, the average across all significant findings was very small with only 1.9% contribution 
to variability.  
The lack of correlation between SAA and spatiotemporal gait characteristics and the 
minimal contribution of SAA to the variability in temporal variability above and beyond that of 
gait speed suggest that the variability in temporal variability parameters is not under the direct 
influence of SAA, and that there must be some other underlying cause for any changes in 
variability. Gait speed was not directly correlated with SAA. These results do not support 
previous work concluding that increased SAA is associated with a decrease in gait speed (Nebes 
et al., 2007; Cao et al., 2008). However, gait speed could be one of the major contributors 
causing the changes in gait variability measures. The average R2 value for only gait speed in the 
model with each of the temporal variability parameters was 0.17 with a maximum of 0.414. The 
largest R2 values were seen with stance time variability. This can be interpreted as the largest 
known contribution accounting for the variability in temporal variability for these participants 
may actually be gait speed, not SAA. Additionally, pilot work conducted prior to the beginning 
of this research project found increased stride time variability with increased SAA during dual-
task walking. While stride time variability was not calculated for this project, it could be 
concluded that SAA has previously demonstrated some impact on gait variability.  
While the underlying cause for changes in variability are unclear from this analysis, the 
lack of significance may again be related to overall participant health. For this analysis, the 
average SAA was slightly less at 0.50 pmole mL atropine equivalent-1 with range of 0-2.05 
pmole mL atropine equivalent-1. Previous work has quantified SAA in the same manner as done 
here, and these results are presented in Section 4.1.2. Comparatively, our participants again have 
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a very low average SAA level and very small variance. If SAA levels were to be higher in this 
population with a larger variance, we would have expected to see some relationships between 
variability and SAA and a larger contribution of SAA to the variability above and beyond that 
explained by average GS. This theory stems from one of the main actions of anticholinergic 
medications in its impact on cognition and attention. As previously mentioned, walking while 
performing a concurrent task involves continuous competition for available resources. 
Specifically, the attention demands of both tasks competing for the limited attention capacity 
could lead to degradation in one or both tasks (Abernethy, 1988; Pashler, 1994; Beauchet & 
Berrut, 2006). If anticholinergics are indeed capable of modifying or limiting the capacity of 
attention, the demands of both tasks will be competing for an even more limited amount of 
attention. As a result, there should be even more significant changes in gait variability (i.e. 
increased variability) and poorer performance on the cognitive challenge task.  
4.2.3 Spatiotemporal Gait Characteristics and WMH 
The second half of Specific Aim 2 was to investigate the relationship between WMH and 
spatiotemporal gait during single-task walking and walking under a dual-task. While the exact 
mechanism of action is unclear, previous work has been done to quantify gait characteristics and 
related them to WMH. Results of this work showed decreased gait speed, increased stride time, 
and increased double support time with increased WMH (Rosano et al., 2006; Murray et al., 
2010). With this, it was hypothesized that with increasing WMH, we would also expect to see 
decreased gait speed but also increased temporal variability. This was tested using two different 
analyses. We first used the Pearson correlation coefficient to identify any relationships between 
gait and WMH across all tasks. Our results showed that none of the spatiotemporal gait 
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characteristics were correlated with WMH. We then repeated this analysis by adjusting for gait 
speed and this time found one significant correlation between STV and SS during the F task. 
However, since this was the only correlation present out of 48 (0.02%), it may actually be due to 
chance or noise within the model that this significant relationship was shown. These results do 
not agree with previous literature. 
The second analysis was performed to understand the contributions of average GS and 
the predictor variables to the variability in temporal variability. Several significant contributions 
of WMH and WMH in the regions of interest were identified except for in cadence variability. 
But, just as in the SAA analysis, the contribution of WMH to the variability of temporal 
variability above and beyond that of average GS was quite small. The average contribution was 
only 2.56% with a range from 0-11%. Moreover, average GS had an average contribution to 
temporal variability of 25.3% with a range of 15-33%. It is difficult to conclude that WMH truly 
contributed a significant amount to temporal variability when the percentage was so small.  
 These results demonstrate that temporal variability is not under the direct control of 
overall WMH or the WMH within the regions of interest selected. While the contributions of 
WMH to the overall variability in temporal variability were significant for a sub-set of variables, 
the actual values of these contributions were very small. From these results, several conclusions 
can be made. First, with respect to this analysis, it appears that gait speed is the largest factor 
affecting variability. This conclusion is in support of work by Kang and Dingwell (2007). By 
modulating gait speed throughout the duration of the 60 second walking trial and between trials, 
it makes sense that participants would become more variable in the number of steps taken, the 
time each foot is on the ground, and the timing between steps. Second, the participants in this 
analysis did demonstrate temporal variability not fully explained by gait speed. Some other 
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underlying factor must be causing these changes. While it is unclear based on the metrics 
obtained in this population, it can be proposed that other aspects inherent with aging including 
the adoption of cautious gait and the fear of falling (Hausdorff et al., 2001; Menz et al., 2003) 
may be the cause of the changes in temporal variability seen here. Third, as mentioned 
throughout this work, the overall health status of the participant population used may have 
limited the results obtained. Work by others measuring WMH in the same manner as conducted 
here was presented in section 4.1.2. For this analysis, the average overall WMH was very small 
at 0.112% total brain volume with an additionally small range of 0.00555-0.452% total brain 
volume. Without a larger magnitude and variance of WMH within the population recruited, it 
may be that the participants did not actually experience the adverse effects associated with WMH 
such as demyelination, loss of axons, gliosis, and dilation of the periventricular space have all 
been associated with WMH (Ota et al., 2010). Without these physiological barriers impacting the 
neural health of our participants, it can be further supported that WMH did not cause the changes 
seen here in temporal variability. 
4.2.4 Spatiotemporal Gait Characteristics and the Combined Effects of SAA and WMH 
The second half of Specific Aim 3 looked to determine if there was a relationship between 
spatiotemporal characteristics under different task conditions with the combined effects of SAA 
and WMH. As was done with the balance outcome measures, this was accomplished using the 
volume of WMH located in the CHOL and NON-CHOL tracts as determined by MRI. Again, 
CHOL are the tracts containing cholinergic fibers while NON-CHOL are the tracts not 
containing cholinergic fibers. It was hypothesized that participants taking anticholinergic 
medications who also showed the presence of WMH within the cholinergic tracts would have 
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increased temporal variability, and this increase would be exaggerated with performing a dual-
task. Using the Pearson correlation, our results indicate that there were four significant 
correlations between temporal variability and WMH when not adjusted for gait speed and only 
three significant correlations when adjusted for gait speed. These significant findings occurred 
during NT conditions in STV, SEV, and CV. However, these findings do not support the 
hypothesis that spatiotemporal gait parameters are affected by the combined interaction of SAA 
and WMH since the findings were not the in the tracts containing cholinergic fibers. When 
looking at the contribution of CHOL to the variability in temporal variability above and beyond 
that explained by gait speed, there were no significant contributions of CHOL to the variability 
of temporal variability above and beyond that attributed to gait speed. While there were some 
significant findings with NON-CHOL, these findings can be considered comparable to those of 
WMH as the non-cholinergic tracts are simply measures of WMH without the presence of 
cholinergic fibers.   
Under these findings, it can be concluded that there were no significant relationships 
between the combined interaction effects of WMH and SAA on temporal variability. This 
conclusion does not come as a surprise. To have seen results in this analysis, we would have 
expected to also see significant relationships of SAA and WMH with temporal variability or at 
least major contributions of SAA and WMH to temporal variability. These relationships were not 
found given the participant sample studied in this analysis. Without significant WMH, the effects 
of anticholinergic medications are not enhanced as would be in the presence of greater WMH. It 
is important to note that for this analysis, six of the 20 participants did not even have detectable 
WMH in the cholinergic tracts. Without the presence of WMH in the tract of interest, the 
correlation analysis is extremely limited. Again, as previously stated, the participants selected for 
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this study were extremely healthy with limited presence of WMH and very low levels of SAA. 
Without a large variance of the predictor variables of interest, it is not surprising that the results 
were very limited.  
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5.0  LIMITATIONS 
5.1 PARTICIPANT CHARACTERISTICS 
The statistical significance of this study may have been compromised due to the lack of large 
variance of predictor variables such as SAA and overall WMH. The screening process for 
participant recruitment was designed to ensure that participants would not be at risk during 
participation in the research protocol, did not have any known conditions that would prevent 
them from standing or walking normally, and did not have any neural changes such as known 
depression or cognitive deficit to interfere with the success of the dual-task. While it is important 
to eliminate these participants from testing if it would be a risk to their safety or if they could not 
perform the tasks, it may be of importance to consider a wider range participants based on 
certain criteria such as medication use. By recruiting participants with a higher chance of 
exhibiting the characteristics of interest such as known anticholinergic use, the results from 
future work with this protocol may show significant findings. 
5.2 TESTING AREA 
While participants were capable of walking for a continuous 60 seconds during each walking 
trial, participants were required to walk on a small, tight circular track to maintain this 
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continuous path. The Vicon motion capture system is limited in the volume of space at which it 
is capable of capturing motion, resulting in tight turns at the end of each straightaway for 
participants to navigate in order to maximize time walked on the straight portion of the track. 
While data was not processed when captured over the turns, participants may have altered their 
gait approximately two steps prior to and after the turns in order to safely navigate them. This 
may have then impacted temporal variability within the straightaways if the participants were not 
able to recover from the alterations made within the turn. It would be ideal if this study could be 
conducted using an instrumented treadmill or shorter protocol duration in a larger room that 
would allow for continuous, straight walking.  
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6.0  CONCLUSION 
The purpose of this research project was to determine whether balance or gait are negatively 
affected by the use of anticholinergic medications, white matter hyperintensities in the brain, and 
the combined effects of both in older adults during single and dual-task conditions. Results from 
this study indicate that there is not a direct relationship between the use of anticholinergic 
medications and the aging of the brain indicated by WMH to balance or gait, regardless of task 
condition. Additionally, the combined effects of WMH and anticholinergic medications were 
also not found to be significantly related to balance or gait, regardless of task. While some 
significant relationships were found, the magnitude of relationships investigated to the actual 
number of findings is so much larger that the significant findings are not enough to provide 
conclusive results. However, findings from this study did confirm several previous works by 
other authors that balance and gait suffer when performed under a dual-task, independent of 
anticholinergic burden and WMH. There was a decline is overall balance performance, decrease 
in gait speed, and increase in temporal variability, putting all of the participants of this study at 
an increased risk for falls when either attempting to maintain balance or walking normally while 
performing a secondary cognitive task. From this, it can be concluded that while WMH and SAA 
are not the direct causes of changes in balance or walking performance in the participants used 
for this analysis, other factors relative to aging including changes in muscular strength, gait 
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speed and fear of falling may be linked to the changes that were seen in the balance and gait 
measures.  
 While the anticipated relationships were not found and limitations of this study exist, this 
work still provides implications for future studies to investigate possible relationships between 
anticholinergic medications and WMH. By recruiting participants based on medication use or 
known MRI findings, a larger variance of predictor variables may allow for relationships 
between the variables of interest to be determined. By better understanding these relationships 
and being able to link changes in balance and gait to specific neural regions of interest and 
quantified medication burden, we may be one step closer to understanding the mechanism of 
action on physical function by the predictor variables. Once this is understood, better care can be 
taken to monitor medication use and provide therapeutic training to people at a higher risk for 
falls as related to medication burden and changes in WMH with age. 
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APPENDIX A 
BALANCE RESULTS 
Table 17: Unadjusted and Adjusted Spearman correlation coefficients and their corresponding p-
values describing the relationship between the COP variables of interest and CHOL, NON-
CHOL, SAA, WMH ALL, AACC, SS, and CC (α=0.05) for EC and EO conditions and all tasks. 
Significance is denoted by an asterisk (*). 
 
Eye Task COP Predictor Variable 
Unadjusted 
Spearman 
Coefficient 
Unadjusted 
Spearman 
p-value 
Adjusted 
Spearman 
Coefficient 
Adjusted 
Spearman 
p-value 
EO NT AP RMS CHOL 0.053 0.82 0.032 0.89 
EO NT AP RMS 
NON-
CHOL 0.36 0.11 0.31 0.19 
EO NT AP RMS SAA -0.20 0.18 -0.21 0.18 
EO NT AP RMS 
WMH 
ALL 0.28 0.096 0.32 0.063 
EO NT AP RMS AACC 0.10 0.56 0.14 0.43 
EO NT AP RMS CC 0.33 0.052 0.38 0.026 * 
EO NT AP RMS SS 0.0045 0.98 0.017 0.92 
EO NT ML RMS CHOL -0.11 0.64 -0.16 0.49 
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Table 17 (continued) 
 
EO NT ML RMS 
NON-
CHOL -0.023 0.92 -0.16 0.49 
EO NT ML RMS SAA -0.15 0.34 -0.14 0.37 
EO NT ML RMS 
WMH 
ALL 0.051 0.77 0.11 0.54 
EO NT ML RMS AACC -0.074 0.67 -0.014 0.94 
EO NT ML RMS CC 0.14 0.41 0.22 0.21 
EO NT ML RMS SS -0.023 0.89 0.0012 0.99 
EO NT PL CHOL 0.12 0.59 0.10 0.67 
EO NT PL NON-CHOL -0.025 0.92 -0.13 0.57 
EO NT PL SAA -0.12 0.43 -0.11 0.49 
EO NT PL WMH ALL -0.063 0.71 0.015 0.93 
EO NT PL AACC -0.17 0.32 -0.087 0.62 
EO NT PL CC 0.081 0.64 0.19 0.26 
EO NT PL SS -0.17 0.33 -0.14 0.42 
EO NT AP VEL CHOL 0.13 0.57 0.11 0.63 
EO NT AP VEL 
NON-
CHOL 0.029 0.99 -0.063 0.79 
EO NT AP VEL SAA -0.16 0.31 -0.15 0.35 
EO NT AP VEL 
WMH 
ALL -0.21 0.23 -0.14 0.41 
EO NT AP VEL AACC -0.23 0.18 -0.15 0.38 
EO NT AP VEL CC -0.066 0.70 0.027 0.88 
EO NT AP VEL SS -0.16 0.35 -0.13 0.44 
EO NT ML VEL CHOL 0.14 0.53 0.13 0.58 
EO NT ML VEL 
NON-
CHOL -0.10 0.66 -0.17 0.46 
EO NT ML VEL SAA -0.11 0.47 -0.098 0.53 
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Table 17 (continued) 
 
EO NT ML VEL 
WMH 
ALL 0.12 0.49 0.19 0.27 
EO NT ML VEL AACC -0.056 0.75 0.019 0.91 
EO NT ML VEL CC 0.25 0.15 0.35 0.041 * 
EO NT ML VEL SS -0.11 0.52 -0.087 0.62 
   
EO F AP RMS CHOL 0.22 0.34 0.21 0.37 
EO F AP RMS 
NON-
CHOL 0.16 0.50 0.14 0.57 
EO F AP RMS SAA -0.10 0.51 -0.099 0.52 
EO F AP RMS 
WMH 
ALL 0.12 0.47 0.13 0.46 
EO F AP RMS AACC 0.12 0.49 0.12 0.48 
EO F AP RMS CC 0.18 0.31 0.18 0.29 
EO F AP RMS SS -0.13 0.44 -0.13 0.45 
EO F ML RMS CHOL -0.029 0.90 -0.051 0.83 
EO F ML RMS 
NON-
CHOL 0.32 0.16 0.27 0.25 
EO F ML RMS SAA -0.016 0.92 -0.0073 0.96 
EO F ML RMS 
WMH 
ALL 0.11 0.54 0.13 0.45 
EO F ML RMS AACC 0.079 0.64 0.11 0.52 
EO F ML RMS CC 0.14 0.40 0.18 0.30 
EO F ML RMS SS -0.028 0.87 -0.018 0.92 
EO F PL CHOL 0.14 0.55 0.14 0.55 
EO F PL NON-CHOL 0.065 0.78 0.082 0.73 
EO F PL SAA 0.069 0.66 0.082 0.60 
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Table 17 (continued) 
 
EO F PL WMH ALL 0.038 0.83 0.067 0.70 
EO F PL AACC -0.021 0.91 0.013 0.94 
EO F PL CC 0.168 0.33 0.21 0.22 
EO F PL SS -0.16 0.34 -0.15 0.38 
EO F AP VEL CHOL 0.24 0.29 0.25 0.30 
EO F AP VEL 
NON-
CHOL 0.079 0.73 0.10 0.67 
EO F AP VEL SAA 0.068 0.66 0.083 0.60 
EO F AP VEL 
WMH 
ALL -0.027 0.88 0.0064 0.97 
EO F AP VEL AACC -0.062 0.72 -0.024 0.89 
EO F AP VEL CC 0.079 0.65 0.13 0.47 
EO F AP VEL SS -0.23 0.18 -0.22 0.21 
EO F ML VEL CHOL 0.013 0.96 0.017 0.94 
EO F ML VEL 
NON-
CHOL -0.0078 0.97 0.0054 0.98 
EO F ML VEL SAA 0.043 0.78 0.05 0.75 
EO F ML VEL 
WMH 
ALL 0.17 0.33 0.18 0.30 
EO F ML VEL AACC 0.086 0.62 0.098 0.57 
EO F ML VEL CC 0.28 0.093 0.31 0.074 
EO F ML VEL SS -0.0022 0.99 0.0011 0.99 
 
EO B AP RMS CHOL 0.0040 0.99 -0.015 0.95 
EO B AP RMS 
NON-
CHOL 0.15 0.53 0.091 0.70 
EO B AP RMS SAA -0.14 0.39 -0.13 0.42 
EO B AP RMS 
WMH 
ALL -0.027 0.88 0.028 0.88 
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Table 17 (continued) 
 
EO B AP RMS AACC -0.10 0.56 -0.042 0.81 
EO B AP RMS CC 0.047 0.79 0.13 0.47 
EO B AP RMS SS -0.082 0.64 -0.059 0.74 
EO B ML RMS CHOL 0.16 0.49 0.14 0.56 
EO B ML RMS 
NON-
CHOL 0.22 0.34 0.13 0.58 
EO B ML RMS SAA -0.25 0.10 -0.24 0.12 
EO B ML RMS 
WMH 
ALL 0.030 0.86 0.10 0.57 
EO B ML RMS AACC -0.0066 0.97 0.076 0.67 
EO B ML RMS CC 0.13 0.45 0.24 0.17 
EO B ML RMS SS -0.23 0.19 -0.21 0.24 
EO B PL CHOL 0.094 0.68 0.085 0.72 
EO B PL NON-CHOL -0.10 0.66 -0.14 0.55 
EO B PL SAA -0.076 0.63 -0.060 0.71 
EO B PL WMH ALL -0.16 0.37 -0.096 0.59 
EO B PL AACC -0.22 0.20 -0.16 0.38 
EO B PL CC -0.030 0.86 0.063 0.73 
EO B PL SS -0.24 0.16 -0.22 0.21 
EO B AP VEL CHOL 0.12 0.60 0.11 0.63 
EO B AP VEL 
NON-
CHOL -0.0078 0.97 -0.037 0.88 
EO B AP VEL SAA -0.041 0.80 -0.016 0.92 
EO B AP VEL 
WMH 
ALL -0.18 0.29 -0.12 0.49 
EO B AP VEL AACC -0.22 0.21 -0.15 0.41 
EO B AP VEL CC -0.058 0.74 0.037 0.83 
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EO B AP VEL SS -0.30 0.085 -0.28 0.11 
EO B ML VEL CHOL 0.15 0.52 0.15 0.53 
EO B ML VEL 
NON-
CHOL -0.19 0.42 -0.19 0.41 
EO B ML VEL SAA -0.069 0.66 -0.063 0.69 
EO B ML VEL 
WMH 
ALL 0.017 0.92 0.048 0.79 
EO B ML VEL AACC -0.083 0.64 -0.051 0.77 
EO B ML VEL CC 0.14 0.42 0.19 0.28 
EO B ML VEL SS -0.17 0.34 -0.15 0.38 
   
EC NT AP RMS CHOL -0.28 0.21 -0.33 0.16 
EC NT AP RMS 
NON-
CHOL 0.41 0.068 0.35 0.13 
EC NT AP RMS SAA 0.097 0.53 0.11 0.49 
EC NT AP RMS 
WMH 
ALL 0.31 0.068 0.36 0.034 * 
EC NT AP RMS AACC 0.23 0.18 0.24 0.18 
EC NT AP RMS CC 0.19 0.27 0.22 0.21 
EC NT AP RMS SS 0.43 0.011 * 0.46 0.0061 * 
EC NT ML RMS CHOL 0.10 0.66 0.096 0.69 
EC NT ML RMS 
NON-
CHOL 0.25 0.27 0.23 0.32 
EC NT ML RMS SAA -0.095 0.54 -0.092 0.56 
EC NT ML RMS 
WMH 
ALL 0.42 0.011 * 0.45 0.0063 * 
EC NT ML RMS AACC 0.34 0.045 * 0.39 0.022 * 
EC NT ML RMS CC 0.45 0.0057 * 0.51 0.0023 * 
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EC NT ML RMS SS 0.21 0.24 0.23 0.20 
EC NT PL CHOL 0.065 0.78 0.059 0.80 
EC NT PL NON-CHOL 0.031 0.89 0.0089 0.97 
EC NT PL SAA -0.088 0.57 -0.078 0.62 
EC NT PL WMH ALL 0.11 0.52 0.14 0.41 
EC NT PL AACC 0.027 0.87 0.12 0.51 
EC NT PL CC 0.21 0.23 0.28 0.10 
EC NT PL SS 0.070 0.69 0.11 0.55 
EC NT AP VEL CHOL 0.14 0.53 0.13 0.57 
EC NT AP VEL 
NON-
CHOL 0.058 0.80 0.019 0.94 
EC NT AP VEL SAA -0.12 0.45 -0.11 0.49 
EC NT AP VEL 
WMH 
ALL -0.037 0.83 -0.0037 0.98 
EC NT AP VEL AACC -0.10 0.55 -0.011 0.95 
EC NT AP VEL CC 0.059 0.73 0.14 0.43 
EC NT AP VEL SS -0.11 0.53 -0.074 0.68 
EC NT ML VEL CHOL 0.093 0.69 0.10 0.68 
EC NT ML VEL 
NON-
CHOL -0.012 0.96 0.0092 0.97 
EC NT ML VEL SAA -0.0073 0.96 -0.00065 0.99 
EC NT ML VEL 
WMH 
ALL 0.29 0.086 0.30 0.085 
EC NT ML VEL AACC 0.17 0.31 0.23 0.20 
EC NT ML VEL CC 0.38 0.022 * 0.43 0.012 * 
EC NT ML VEL SS 0.26 0.14 0.27 0.12 
   
EC F AP RMS CHOL 0.13 0.59 0.10 0.67 
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EC F AP RMS 
NON-
CHOL 0.29 0.19 0.20 0.40 
EC F AP RMS SAA -0.053 0.73 -0.035 0.82 
EC F AP RMS 
WMH 
ALL 0.27 0.11 0.37 0.031 * 
EC F AP RMS AACC 0.16 0.34 0.24 0.16 
EC F AP RMS CC 0.30 0.080 0.39 0.023 * 
EC F AP RMS SS 0.23 0.19 0.30 0.086 
EC F ML RMS CHOL 0.0040 0.99 -0.031 0.90 
EC F ML RMS 
NON-
CHOL 0.021 0.93 -0.098 0.68 
EC F ML RMS SAA -0.18 0.25 -0.17 0.29 
EC F ML RMS 
WMH 
ALL 0.13 0.46 0.16 0.35 
EC F ML RMS AACC 0.11 0.51 0.24 0.17 
EC F ML RMS CC 0.18 0.30 0.27 0.12 
EC F ML RMS SS 0.30 0.082 0.35 0.041 * 
EC F PL CHOL 0.14 0.55 0.12 0.60 
EC F PL NON-CHOL 0.0026 0.99 -0.055 0.82 
EC F PL SAA -0.16 0.31 -0.15 0.34 
EC F PL WMH ALL 0.11 0.54 0.13 0.47 
EC F PL AACC 0.050 0.77 0.15 0.40 
EC F PL CC 0.22 0.20 0.30 0.008 
EC F PL SS 0.16 0.37 0.19 0.29 
EC F AP VEL CHOL 0.089 0.70 0.074 0.76 
EC F AP VEL 
NON-
CHOL 0.053 0.82 -0.020 0.99 
EC F AP VEL SAA -0.099 0.52 -0.089 0.57 
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EC F AP VEL 
WMH 
ALL 0.11 0.51 0.14 0.42 
EC F AP VEL AACC 0.047 0.79 0.15 0.49 
EC F AP VEL CC 0.23 0.17 0.31 0.071 
EC F AP VEL SS 0.11 0.52 0.15 0.41 
EC F ML VEL CHOL 0.067 0.87 0.054 0.82 
EC F ML VEL 
NON-
CHOL -0.039 0.867 -0.089 0.71 
EC F ML VEL SAA -0.17 0.28 -0.16 0.30 
EC F ML VEL 
WMH 
ALL 0.16 0.36 0.16 0.35 
EC F ML VEL AACC 0.11 0.53 0.17 0.34 
EC F ML VEL CC 0.24 0.16 0.28 0.10 
EC F ML VEL SS 0.20 0.26 0.21 0.23 
   
EC B AP RMS CHOL 0.080 0.73 0.066 0.78 
EC B AP RMS 
NON-
CHOL 0.082 0.72 0.033 0.89 
EC B AP RMS SAA -0.19 0.90 -0.0085 0.96 
EC B AP RMS 
WMH 
ALL -0.046 0.79 0.016 0.93 
EC B AP RMS AACC -0.075 0.67 0.083 0.64 
EC B AP RMS CC 0.020 0.91 0.16 0.38 
EC B AP RMS SS -0.056 0.75 0.011 0.95 
EC B ML RMS CHOL 0.24 0.30 0.24 0.31 
EC B ML RMS 
NON-
CHOL 0.034 0.88 0.024 0.92 
EC B ML RMS SAA -0.15 0.32 -0.15 0.33 
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EC B ML RMS 
WMH 
ALL 0.11 0.51 0.13 0.45 
EC B ML RMS AACC 0.0041 0.98 0.10 0.56 
EC B ML RMS CC 0.22 0.20 0.31 0.076 
EC B ML RMS SS 0.043 0.81 0.075 0.67 
EC B PL CHOL 0.082 0.72 0.074 0.76 
EC B PL NON-CHOL 0.0052 0.98 -0.027 0.91 
EC B PL SAA -0.15 0.34 -0.14 0.38 
EC B PL WMH ALL -0.070 0.69 -0.037 0.83 
EC B PL AACC -0.13 0.45 -0.035 0.84 
EC B PL CC 0.069 0.69 0.15 0.39 
EC B PL SS -0.078 0.65 -0.038 0.83 
EC B AP VEL CHOL 0.11 0.62 0.10 0.66 
EC B AP VEL 
NON-
CHOL 0.027 0.91 -0.016 0.95 
EC B AP VEL SAA -0.10 0.50 -0.091 0.56 
EC B AP VEL 
WMH 
ALL -0.14 0.41 -0.10 0.56 
EC B AP VEL AACC -0.19 0.26 -0.094 0.60 
EC B AP VEL CC 0.0093 0.96 0.095 0.59 
EC B AP VEL SS -0.12 0.50 -0.076 0.67 
EC B ML VEL CHOL 0.13 0.58 0.12 0.60 
EC B ML VEL 
NON-
CHOL 0.043 0.85 0.026 0.91 
EC B ML VEL SAA -0.17 0.28 -0.16 0.31 
EC B ML VEL 
WMH 
ALL 0.044 0.8 0.069 0.69 
EC B ML VEL AACC -0.038 0.83 0.025 0.89 
 107 
Table 17 (continued) 
 
EC B ML VEL CC 0.15 0.39 0.20 0.25 
EC B ML VEL SS -0.013 0.94 0.017 0.93 
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APPENDIX B 
GAIT RESULTS 
Table 18: Unadjusted and adjusted Pearson correlation coefficients and their corresponding p-
values describing the relationship between Average GS, the gait variability variables of interest 
and CHOL, NON-CHOL, SAA, WMH ALL, AACC, SS, and CC (α=0.05) for all tasks. 
Significance is denoted by an asterisk (*). 
 
Task Variability Measure 
Predictor 
Variable 
Unadjusted 
Pearson 
Coefficient 
Unadjusted 
Pearson 
p-value 
Adjusted 
Pearson 
Coefficient 
Adjusted 
Pearson 
p-value 
NT Average GS CHOL -0.022 0.93 -- -- 
NT Average GS NON-CHOL -0.22 0.36 -- -- 
NT Average GS SAA 0.22 0.17 -- -- 
NT Average GS WMH ALL 0.10 0.58 -- -- 
NT Average GS AACC 0.16 0.37 -- -- 
NT Average GS CC 0.11 0.53 -- -- 
NT Average GS SS 0.016 0.93 -- -- 
F Average GS CHOL 0.028 0.91 -- -- 
F Average GS NON-CHOL -0.19 0.41 -- -- 
F Average GS SAA 0.20 0.22 -- -- 
F Average GS WMH ALL 0.10 0.57 -- -- 
F Average GS AACC 0.16 0.39 -- -- 
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Table 18 (continued) 
 
F Average GS CC 0.11 0.54 -- -- 
F Average GS SS 0.019 0.91 -- -- 
B Average GS CHOL -0.078 0.74 -- -- 
B Average GS NON-CHOL -0.27 0.26 -- -- 
B Average GS SAA 0.082 0.61 -- -- 
B Average GS WMH ALL 0.095 0.61 -- -- 
B Average GS AACC 0.16 0.37 -- -- 
B Average GS CC 0.078 0.67 -- -- 
B Average GS SS 0.032 0.86 -- -- 
NT CV CHOL 0.15 0.53 0.15 0.54 
NT CV NON-CHOL 0.56 0.01 * 0.56 0.012 * 
NT CV SAA 0.071 0.66 0.093 0.58 
NT CV WMH ALL 0.19 0.27 0.20 0.26 
NT CV AACC 0.062 0.74 0.076 0.69 
NT CV CC 0.22 0.23 0.23 0.21 
NT CV SS 0.095 0.61 0.096 0.61 
F CV CHOL 0.16 0.50 0.16 0.51 
F CV NON-CHOL -0.024 0.92 -0.027 0.91 
F CV SAA -0.12 0.47 -0.12 0.49 
F CV WMH ALL 0.010 0.96 0.016 0.93 
F CV AACC -0.0048 0.98 0.0083 0.96 
F CV CC 0.14 0.44 0.15 0.41 
F CV SS 0.037 0.84 0.039 0.83 
B CV CHOL 0.19 0.43 0.19 0.43 
B CV NON-CHOL 0.16 0.49 0.19 0.45 
B CV SAA 0.029 0.86 0.028 0.87 
B CV WMH ALL 0.093 0.60 0.10 0.57 
B CV AACC 0.0088 0.96 0.031 0.87 
B CV CC 0.19 0.30 0.20 0.28 
B CV SS 0.042 0.82 0.046 0.81 
NT DSV CHOL -0.0039 0.99 -0.016 0.95 
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Table 18 (continued) 
 
NT DSV NON-CHOL 0.94 0.084 0.34 0.15 
NT DSV SAA 0.060 0.71 0.19 0.25 
NT DSV WMH ALL 0.17 0.34 0.23 0.20 
NT DSV AACC 0.077 0.68 0.15 0.42 
NT DSV CC 0.22 0.22 0.29 0.12 
NT DSV SS -0.021 0.91 -0.016 0.93 
F DSV CHOL 0.090 0.71 0.10 0.68 
F DSV NON-CHOL -0.055 0.82 -0.11 0.65 
F DSV SAA -0.098 0.55 -0.041 0.81 
F DSV WMH ALL 0.033 0.85 0.066 0.72 
F DSV AACC 0.0062 0.97 0.052 0.78 
F DSV CC 0.16 0.38 0.20 0.28 
F DSV SS 0.070 0.70 0.079 0.67 
B DSV CHOL 0.16 0.51 0.15 0.54 
B DSV NON-CHOL 0.11 0.64 0.074 0.76 
B DSV SAA -0.021 0.90 0.00021 0.99 
B DSV WMH ALL 0.15 0.41 0.18 0.33 
B DSV AACC 0.036 0.85 0.082 0.66 
B DSV CC 0.25 0.17 0.28 0.13 
B DSV SS 0.063 0.73 0.073 0.70 
NT STV CHOL 0.074 0.76 0.076 0.76 
NT STV NON-CHOL 0.58 0.0075 * 0.57 0.010 * 
NT STV SAA -0.095 0.56 0.063 0.70 
NT STV WMH ALL 0.14 0.44 0.26 0.15 
NT STV AACC 0.081 0.66 0.23 0.22 
NT STV CC 0.14 0.44 0.26 0.15 
NT STV SS 0.053 0.77 0.077 0.68 
F STV CHOL 0.17 0.47 0.21 0.40 
F STV NON-CHOL 0.046 0.85 -0.046 0.85 
F STV SAA -0.28 0.084 -0.21 0.20 
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Table 18 (continued) 
 
F STV WMH ALL 0.046 0.80 0.11 0.54 
F STV AACC 0.056 0.76 0.15 0.43 
F STV CC 0.091 0.62 0.16 0.39 
F STV SS 0.32 0.070 0.37 0.038 * 
B STV CHOL 0.19 0.42 0.18 0.47 
B STV NON-CHOL 0.35 0.13 0.26 0.29 
B STV SAA 0.013 0.94 0.073 0.66 
B STV WMH ALL 0.13 0.48 0.23 0.20 
B STV AACC 0.022 0.91 0.14 0.44 
B STV CC 0.21 0.25 0.31 0.090 
B STV SS 0.023 0.90 0.051 0.79 
NT SEV CHOL 0.030 0.90 0.022 0.93 
NT SEV NON-CHOL 0.49 0.027 * 0.45 0.051 
NT SEV SAA -0.078 0.63 0.038 0.82 
NT SEV WMH ALL 0.087 0.63 0.16 0.38 
NT SEV AACC -0.0093 0.96 0.075 0.69 
NT SEV CC 0.098 0.59 0.17 0.36 
NT SEV SS 0.12 0.50 0.15 0.43 
F SEV CHOL 0.15 0.53 0.19 0.44 
F SEV NON-CHOL 0.10 0.67 0.010 0.97 
F SEV SAA -0.17 0.29 -0.10 0.56 
F SEV WMH ALL -0.047 0.80 0.0057 0.98 
F SEV AACC -0.0043 0.98 0.077 0.69 
F SEV CC -0.027 0.89 0.029 0.88 
F SEV SS 0.21 0.25 0.25 0.18 
B SEV CHOL 0.31 0.19 0.31 0.21 
B SEV NON-CHOL 0.58 0.0088 * 0.54 0.021 * 
B SEV SAA 0.11 0.51 0.17 0.31 
B SEV WMH ALL 0.099 0.59 0.18 0.33 
B SEV AACC 0.023 0.90 0.14 0.47 
B SEV CC 0.088 0.64 0.15 0.42 
B SEV SS 0.18 0.34 0.23 0.21 
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Table 19: R2 values obtained by regressing each gait variability measure on average GS alone 
(A), each predictor variable only (B), and on average GS and each predictor variable combined 
(C). The added value of each predictor variable is quantified using the R2 difference between 
models C and A. Statistical significance of the combined effects was set at α=0.05 and is denoted 
by an asterisk. 
 
Task Variability Measure 
Predictor 
Variable 
GS 
Only 
(A) 
Predictor 
Only (B) 
GS & 
Predictor 
(C) 
Δ R2 
(C-A) 
p-value 
of Δ R2 
NT CV CHOL 0.0037 0.022 0.026 0.022 0.80 
NT CV NON-CHOL 0.0037 0.32 0.32 0.32 0.038 * 
NT CV SAA 0.0072 0.0051 0.016 0.0088 0.75 
NT CV WMH ALL 0.0074 0.037 0.049 0.042 0.46 
NT CV AACC 0.0074 0.008 0.019 0.012 0.74 
NT CV CC 0.0074 0.054 0.069 0.062 0.33 
NT CV SS 0.0057 0.0089 0.015 0.0093 0.81 
F CV CHOL 0.0002 0.026 0.026 0.026 0.80 
F CV NON-CHOL 0.0002 0.0006 0.0009 0.0007 0.99 
F CV SAA 0.0005 0.014 0.014 0.014 0.77 
F CV WMH ALL 0.002 0.0001 0.0022 0.0002 0.97 
F CV AACC 0.002 0.0001 0.002 0 0.97 
F CV CC 0.002 0.018 0.022 0.02 0.71 
F CV SS 0.0068 0.0014 0.0082 0.0014 0.88 
B CV CHOL 0.0036 0.035 0.040 0.036 0.71 
B CV NON-CHOL 0.0036 0.026 0.038 0.034 0.72 
B CV SAA 0.0003 0.0008 0.0011 0.0008 0.98 
B CV WMH ALL 0.0063 0.0087 0.017 0.011 0.77 
B CV AACC 0.0063 0.0008 0.0083 0.002 0.88 
B CV CC 0.0063 0.039 0.05 0.044 0.45 
B CV SS 0.0173 0.0017 0.019 0.0017 0.75 
NT DSV CHOL 0.22 0 0.22 0 0.12 
NT DSV NON-CHOL 0.22 0.156 0.31 0.09 0.042 * 
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Table 19 (continued) 
 
NT DSV SAA 0.22 0.0036 0.25 0.03 0.0054 * 
NT DSV WMH ALL 0.15 0.028 0.20 0.05 0.034 * 
NT DSV AACC 0.15 0.0016 0.17 0.02 0.061 
NT DSV CC 0.15 0.033 0.21 0.06 0.026 * 
NT DSV SS 0.14 0.0004 0.14 0 0.11 
F DSV CHOL 0.067 0.0081 0.077 0.01 0.51 
F DSV NON-CHOL 0.067 0.003 0.079 0.012 0.50 
F DSV SAA 0.092 0.0096 0.093 0.001 0.16 
F DSV WMH ALL 0.063 0.0011 0.067 0.004 0.34 
F DSV AACC 0.063 0.0001 0.064 0.001 0.36 
F DSV CC 0.063 0.020 0.095 0.032 0.21 
F DSV SS 0.076 0.0049 0.082 0.0060 0.29 
B DSV CHOL 0.024 0.025 0.045 0.021 0.68 
B DSV NON-CHOL 0.024 0.013 0.029 0.005 0.78 
B DSV SAA 0.068 0.0005 0.068 0 0.27 
B DSV WMH ALL 0.050 0.022 0.079 0.0290 0.28 
B DSV AACC 0.050 0.0026 0.059 0.0090 0.39 
B DSV CC 0.050 0.064 0.13 0.080 0.12 
B DSV SS 0.065 0.0039 0.071 0.0060 0.35 
NT STV CHOL 0.35 0.0055 0.36 0.010 0.024 * 
NT STV NON-CHOL 0.35 0.33 0.56 0.21 0.0009 * 
NT STV SAA 0.41 0.0091 0.42 0.010 <0.0001 * 
NT STV WMH ALL 0.38 0.019 0.42 0.040 0.0002 * 
NT STV AACC 0.38 0.001 0.40 0.020 0.0004 * 
NT STV CC 0.38 0.0088 0.41 0.030 0.0003 * 
NT STV SS 0.35 0.0028 0.36 0.010 0.0016 * 
F STV CHOL 0.20 0.029 0.23 0.030 0.10 
F STV NON-CHOL 0.20 0.0022 0.202 0.0020 0.15 
F STV SAA 0.26 0.077 0.30 0.040 0.0015 * 
F STV WMH ALL 0.20 0.0021 0.21 0.010 0.028 * 
F STV AACC 0.20 0.0001 0.21 0.010 0.028 * 
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F STV CC 0.20 0.0027 0.21 0.010 0.025 * 
F STV SS 0.21 0.11 0.32 0.11 0.0037 * 
B STV CHOL 0.26 0.037 0.28 0.020 0.061 
B STV NON-CHOL 0.26 0.12 0.31 0.050 0.045  * 
B STV SAA 0.32 0.0002 0.33 0.010 0.0007 * 
B STV WMH ALL 0.32 0.016 0.36 0.040 0.001 * 
B STV AACC 0.32 0 0.34 0.020 0.0018 * 
B STV CC 0.32 0.033 0.38 0.060 0.0005 * 
B STV SS 0.33 0.0005 0.33 0 0.0027 * 
NT SEV CHOL 0.21 0.0009 0.21 0 0.14 
NT SEV NON-CHOL 0.21 0.24 0.37 0.16 0.020 * 
NT SEV SAA 0.25 0.006 0.25 0 0.0053 * 
NT SEV WMH ALL 0.23 0.0075 0.24 0.010 0.013 * 
NT SEV AACC 0.23 0.001 0.23 0 0.018 * 
NT SEV CC 0.23 0.0052 0.25 0.020 0.013 * 
NT SEV SS 0.21 0.015 0.23 0.020 0.023 * 
F SEV CHOL 0.25 0.024 0.27 0.020 0.077 
F SEV NON-CHOL 0.25 0.011 0.25 0 0.11 
F SEV SAA 0.20 0.0303 0.21 0.010 0.0142 * 
F SEV WMH ALL 0.18 0.0022 0.18 0 0.047 * 
F SEV AACC 0.18 0.0027 0.19 0.010 0.046 * 
F SEV CC 0.18 0.0041 0.18 0 0.047 * 
F SEV SS 0.21 0.046 0.26 0.050 0.015 * 
B SEV CHOL 0.19 0.098 0.27 0.080 0.080 
B SEV NON-CHOL 0.19 0.34 0.43 0.24 0.012 * 
B SEV SAA 0.21 0.012 0.24 0.03 0.0077 * 
B SEV WMH ALL 0.25 0.0097 0.28 0.03 0.0075 * 
B SEV AACC 0.25 0 0.27 0.02 0.0099 * 
B SEV CC 0.25 0.0049 0.27 0.02 0.0088 * 
B SEV SS 0.29 0.032 0.33 0.04 0.0036 * 
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